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93. ABSTRACT
Dental implants have been remarkably improved in the past half century: Cumulative 
success rates at 10 years are satisfactory, about 88% for maxillary and 93% for 
mandibular implants. Loosening of dental implants is, however, a major complication 
to be faced, with many risk factors affecting loosening. No matter what these risk 
factors are, they affect the pathological biological cascades in peri-implant support 
tissues. This study focused on proteinases and cytokines able to mediate extracellular 
matrix destruction in peri-implant support tissues during loosening. 
Collagenase-2 (a time-resolved immunofluorometric assay), collagenase-3 (a 
quantitative immunoblot) and gelatinase-B (a modified urokinase assay) were 
measured in peri-implant sulcus fluid (PISF). The gingival index did not correlate 
with the degrees of peri-implant vertical bone loss (0.6 ± 0.1 in patients with < 1mm 
loss, 0.6 ± 0.5 in patients with 1 to 3 mm loss, and 1.2 ± 0.3 in patients with > 3 mm 
loss, p > 0.05, Kruskall-Wallis test). Collagenase-2 (2021 ± 1038, p < 0.05) and 
collagenase-3 (16 ± 4, p < 0.05) in PISF were higher in the group with > 3 mm bone 
loss than in the other two groups with either 1 to 3 mm loss (1265 ± 508 and 12 ± 2) 
or bone loss < 1 mm (861 ± 164 and 10 ± 1) (Kruskall-Wallis test). 
Total gelatinase-B (r = 0.55, p = 0.02) and activated gelatinase-B levels (r = 0.52, p =
0.003) in PISF correlated with the peri-implant vertical bone loss (Spearman's rank 
correlation test). Total (1375[1633]) and activated gelatinase-B (458 [979]) levels in 
the high-loss group (> 3 mm) were higher than in the 1 to 3 mm (250[533]; 166[200]) 
and < 1 mm groups (183[480]; 133[225]). Activated gelatinase-B level (225[267]) in 
the GI > 0.5 group was increased compared to GI = 0 (50[125]) and ? 0.5 groups 
(216[375]) (Rank sum test). 
Immunohistochemical staining was used to detect cellular fibronectin (cFN) in 
gingival tissue. cFN was found in epithelial basement membrane, connective tissue 
papillae, walls of blood vessels, and fibroblasts in lamina propria. Computerized 
image analysis was applied for quantitation of cFN. cFN staining in the loosened 
implant group (33 ± 5% positive staining, p < 0.05) was high, but low in the 
periodontitis group (6 ± 1%, p < 0.05) compared to that in normal controls (12 ± 1%). 
Collagenase-cleaved collagen type I 3/4 carboxy-terminal neoepitope (COL1-3/4C) 
antibody was used to detect gingival COL1-3/4C. Moderate staining was visible in 
connective tissue bordering the sulcular and junctional epithelium, surrounding some 
of the fibroblasts, and in some areas infiltrated by inflammatory mononuclear cells. 
COL1-3/4C staining in chronic periodontitis was more intense and extensive (6.3 ± 
1.2%) than that of controls (1.6 ± 0.7%, unpaired student t-test, p < 0.01). 
Interleukin-1? (IL-1?), tumor necrosis factor (TNF-?), IL-6, platelet-derived growth 
factor (PDGF-A), and transforming growth factor-? (TGF-?) were studied as 
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potential components of an osteoclast-stimulating cytokine network by 
immunohistochemical staining. Many of the macrophage-like cells in perivascular 
infiltrates in chronic periodontitis and peri-implantitis contained IL-1?, TNF-?, IL-6, 
PDGF-A, and TGF-?. In addition, all foreign body giant cells, found only in peri-
implantitis tissues, contained these cytokines. Basal cells of epithelium and fibroblast-
like cells contained IL-1?, TNF-?, IL-6, PDGF-A, and TGF-?. The cytokine-staining-
intensity in epithelium was most conspicuous in chronic periodontitis, followed by 
peri-implantitis, and healthy controls, ranked in that order. All cells containing 
cytokines were included in the morphometric calculations. The percentage of TNF-?,
IL-1?, and IL-6 immunoreactive cells was relatively high in peri-implantitis and 
chronic periodontitis (p < 0.05). 
It can thus be concluded that collagenase-2 and -3 and gelatinase-B are associated 
with peri-implant bone loss. Host collagenases produced by the sulcular and 
junctional epithelium, fibroblasts, and monocytes/macrophages are able to cleave 
across the triple helical collagen fibrils in gingival tissue in chronic periodontitis. The 
low expression of cellular fibronectin synthesis in chronic periodontitis could be due 
to its degradation by human neutrophil elastase. The fact that cFN expression was 
relatively high in peri-implantitis suggests that the processes associated with 
loosening of natural teeth and dental implants differ. The osteoclast-activity cytokines 
produced in the supporting soft tissues probably stimulate osteoclasts, leading to the 
alveolar bone loss in a paracrine manner. Therefore, these proteinases and cytokines 
may conduct extracellular matrix destruction in peri-implant support tissues during 
loosening of dental implants. Monitoring the progression of loosening will be helpful 
in its prevention and treatment. 
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4. INTRODUCTION 
Introduction of the concept of osseointegration in the 1950’s remarkably improved 
dental implants. They can serve to replace teeth missing or lost for various reasons 
such as congenital anodontia, traumatic loss of teeth, cancer, root caries, and chronic 
periodontitis (Gassner et al., 2000; Gurlek et al., 1998; McMillan et al., 1998). They 
are very useful in the restoration of tooth function and aesthetics (Adell et al., 1985). 
Many clinical dental implant systems have been developed. Dental implants can be 
used as the sole form of therapy or can function together with other dental treatment 
methods (Callan et al., 2000). When good-quality dental implants and techniques are 
used, implants show similar cumulative success rates at 10 years after implantation. 
The 10-year cumulative success rates are about 88% for maxillary and 93% for 
mandibular implants (O'Roark, 1997), but some implants are lost as a result of 
primary failure or by loosening, a mode of failure resulting from implant movement 
or migration in the bone (Franz, 1997). Unfortunately, these patients, who are mostly 
about 60 years old, are still quite young in terms of current human longevity (Pihakari 
et al., 1999). As a result of failure or loosening of the implants and the longevity of 
the patients, some patients would later need to be re-implanted. But often the 
possibilities for revision operations are limited, due to general and local circumstances 
(Oikarinen et al., 1995). The high and increasing number of dental implantations 
performed (Kronstrom et al., 2002) is evidence that loosening of dental implants is a 
common complication affecting thousands of patients annually worldwide. 
Many important risk factors contribute to this loosening, such as non-ideal 
implantation techniques, oral bacterial pathogens (el Askary et al., 1999; Leonhardt et
al., 1999), bio-mechanical overload (Tonetti and Schmid, 1994), and use of non-
completely biocompatible implants (Gross, 1988). Biocompatibility refers to the 
tissue friendliness of the implant or compatibility of a material (Franz, 1997). Most 
CE-labeled and FDA-approved dental implants are nowadays very biocompatible in 
the human body and provide good success rates. Not only are such mainstream dental 
implants used, but also low quality implants, still widely used worldwide, initiate 
adverse host tissue responses and contribute to premature failure and loosening 
(Santavirta et al., 1999). The most prominent pathological feature of the loosening of 
dental implants is a progressive loss of peri-implant support tissues (Schwartz et al., 
1997; Esposito et al., 1998b), to which many proteinases as well as osteoclast-
mediated bone resorption are related in the process called peri-implantitis (Ingman et
al., 1994; Teronen et al., 1997; van der Zee et al., 1997; Klinger et al., 1998). 
The focus of this thesis is on the relationship between the extracellular matrix 
providing peri-implant tissue support and the tissue-destructive proteinases and 
osteoclast active cytokines. It is important to understand adverse host responses 
induced by non-ideal and non-compatible implant materials, because this may help to 
improve diagnosis, prevention, and treatment of implant loosening to the benefit of 
thousands of implant patients in the future. 
12
5. REVIEW OF THE LITERATURE
1. OSSEOINTEGRATION
The dream of using dental implants can be traced back to ancient times. A tooth-
shaped iron implant has been reported in a 2000-year-old human skull (Crubezy et al., 
1998). Shells and ivory have been tried as dental implants in the past. Unfortunately, 
there were no great breakthroughs in implant materials and implantation methods until 
1952. 
That year Professor Per-Ingvar Brånemark found that a titanium implant bonds to 
living bone. He called the phenomenon osseointegration, which means that the 
titanium implant is structurally integrated into living bone with a very high degree of 
predictability without inflammation in soft and interface tissues or fixture rejection 
(Brånemark et al., 1977). After that finding, most innovations have dealt with 
implant-coating materials, and implants having hydroxyapatite, ceramic, and 
endopore surfaces were introduced (Lacefield, 1988; Albert and Bergeron, 1998). 
Diamond-coated implants developed in Finland are undergoing pre-clinical research 
(Aspenberg et al., 1996; Santavirta et al., 1999; Santavirta, 2003). The concept of 
osseointegration has thus significantly broadened from its original sense to its 
definition as a direct structural and functional connection between living alveolar 
bone and the dental implant as a load-carrier (Stanford and Keller, 1991). 
Currently, about 70% of Norwegian residents are aware of dental implants (Berge, 
2000), and 51% of the Swedes would like to have dental implants (Palmqvist et al., 
1991). On the other hand, in European countries 20% of dentists offer implant 
services (Millennium Research Group, 2002). Dental implants are quite expensive 
compared to some other conventional dental treatments: One dental implant costs 
about $1,250 in the USA (Davidoff, 2002). Implant cost-effectiveness should still be 
improved (Lewis, 1998). Nowadays, 4.8% of people in Sweden and 2.5% of people in 
Denmark who are from 45 to 69 years old have dental implants (Kronstrom et al., 
2002). Therefore, the discovery of osseointegration was such a milestone in dental 
implantology. Below a short description is provided of those conditions which can be 
treated with dental implants. 
2. END-STAGE LOSS OF TOOTH/TEETH
2.1 Congenital anodontia. Congenital anodontia is a genetic disease characterized by 
partial or complete absence of the primary or permanent teeth. Hereditary anodontia 
may occur in the whole maxilla and mandibula or in both. It is referred to as complete 
anodontia. In non-hereditary anodontia, one usually loses one tooth or several teeth 
(Yanagida and Mori, 1990). This is called partial anodontia or hypodontia, a 
subdivision of anodontia. Implants can be applied to support prostheses in both cases 
in children and adults (McMillan et al., 1998). 
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2.2 Trauma. Traumatic loss of a tooth or teeth usually involves the central incisors. 
This occurs usually in sports, such as skiing, boxing or motor sports (Borgogna et al.,
1984; Gassner et al., 2000; Levine et al., 2001). A car accident is also a common 
cause (Huelke and Sherman, 1973). Trauma victims are usually young with high 
quality alveolar bone, and an implant prosthesis is the best way to restore the missing 
tooth or teeth (Sclaroff et al., 2000). It has been calculated that about 5.6% of dental 
implants in Finland are performed in patients younger than 20 years old (Pihakari et
al., 1999). For some traumatic root fractures, immediate implantation is useful, means 
that the implant is placed immediately after the tooth has been lost, without any delay 
(Hernandez and Balshi, 1998; Touati and Guez, 2002). Implants are also helpful in 
war-injured patients (Motamedi et al., 1999). 
2.3 Cancer. Nearly 30,000 new head and neck cancer cases were detected in the USA 
in 1991, with surgical operations probably the first-choice treatment in most of those 
cases (Caplan and Weintraub, 1993). Damage to mandibular or maxillary bone can 
often not be avoided, so facial reconstructions and occlusal restorations are required, 
with dental implants often the best mode of treatment (Gurlek et al., 1998; Ueda et al., 
1999; Kovacs et al., 2000). 
2.4 Root caries and periodontitis. Nowadays people are living longer than ever before 
(Guyer et al., 2000). It has been estimated that in the USA over 40% of people over 
65 years old are edentulous (Caplan and Weintraub, 1993). A similar survey showed 
that in the UK 37.6% of those more than 70 years old are edentulous (Douglass et al., 
1993). About 0.05% of the Finns become edentulous every year (Takala et al., 1994). 
Edentulousness has several causes: 70% of the cases are explained by root caries and 
a further 20% by periodontal diseases (Takala et al., 1994). One similar study has 
shown that in the USA, 22.5% of the population suffers from root caries (Winn et al., 
1996). In Europe, about 20% to 30% of the population suffers from periodontal 
diseases (Reich, 2001). Utilization of dental implants, which significantly improve 
mastication and speech, improves the condition of both edentulous and root caries 
patients (Mangano and Bartolucci, 2001). 
To summarize, dental implants efficiently restore both the function and the aesthetics 
of the teeth in many conditions associated with missing or lost teeth, when used as the 
only modality of treatment or together with other conventional dental techniques 
(Searson and Meredith, 1997). Because dental implants must meet different types of 
demands, multiple kinds of dental implant systems have been designed. 
3. DENTAL IMPLANT CATEGORIES 
3.1 Implant categories and their indications for use. Dental implants are classified into 
four groups according to the method used for their fixation to host structures. These 
categories are endosseous, ramus frame, subperiosteal, and transosteal implants. 
Endosseous implants are further divided into root (cylindrical) and blade (plate) 
implants (Dental implants, NIH Consensus Statement, 1988) (Table 1). Endosseous 
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implants form the most widely used implant group. The quantity and quality of 
alveolar bone is the most important determinant for the outcome of dental implants 
including their success rates (life in service).
Table 1: Dental implant types and indications for their use 
Implant type Alveolar bone Maxilla Mandibular 
Partially 
edentulous 
Completely 
edentulous 
Endosseous adequate bone 
(width and 
height) 
? ? ? ?
Ramus frame enough 
anterior bone 
? ?
Subperiosteal, 
complete, 
unilateral, 
circumferential 
adequate bone 
(width and 
height) 
? ? ? ?
Transosteal, 
staple, single 
pin, multiple pin 
adequate 
anterior bone 
?? ? ?
? means that implantation can be performed at this site. 
     
          
Figure 1. Schematic diagram of an endosseous dental 
implant and a tooth. Note that the implant lacks the 
periodontal ligament and is dependent on direct bone 
support (osseofixation). 
3.2 Some clinical implant categories. In terms of surgical 
procedures, dental implants are grouped as one-stage 
(Barber et al., 1996) and two-stage operative systems 
(Babbush and Shimura, 1993). In a one- stage implant, 
the root and healing abutment are installed in one 
operation. In a two- stage implant, the root and the cover
screw are implanted in the first operation and covered by a periosteal and mucosal 
flap. They are revealed in a second operation after osseointegration (usually 3 months 
in the mandible and 6 months in the maxilla), in which the cover screw is replaced 
with a healing abutment. In terms of applying loading, the implant systems can be 
divided into those which are subjected to immediate or to non-immediate loading 
(Ibanez and Jalbout, 2002). Classically, 3 (for mandible) to 6 (for maxilla) months are 
allowed for osseointegration before loading (Brosh et al., 1995; Buser et al., 2000). 
Now, in some cases suprastructures are installed all at once, and functional loading is 
allowed immediately after implantation. This is practically more acceptable for the 
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patients than a 3-6 month long waiting period (Ericsson and Nilner, 2002). All theses 
implant technologies are widely used in clinics and affect implant success rates 
(Callan et al., 2000). 
4. DENTAL IMPLANT SUCCESS ANALYSIS
4.1 Implant success criteria. Criteria are required for the definition of implant success 
vs loosening or failure. This is important in evaluation of scientific implant 
biomaterials and comparison of clinical investigation of multiple implant systems. In 
1978, the first success criteria were suggested by the US National Institutes of Health. 
They includes “1) bone loss no greater than one-third of the vertical height of the 
implant; 2) good occlusal balance and vertical dimension; 3) gingival inflammation 
amenable to treatment; 4) mobility of less than 1 mm in any direction; 5) absence of 
symptoms and infection; 6) absence of damage to adjacent teeth; 7) absence of 
parathesia or anesthesia or violation of the mandibular canal, maxillary sinus or floor 
of the nasal passage; 8) healthy collagenous tissue without polymorphonuclear 
infiltration; 9) provision of functional service for five years in 75% of the cases” 
(Dental Implants, NIH Consensus Statement, 1978). Unfortunately, the criteria could 
not be met by many dental implants at that time. 
In 1986, modified criteria were suggested by Albrektsson and co-authors: “1) 
implants are clinically immobile; 2) a radiograph not demonstrating any evidence of 
peri-implant radiolucency; 3) vertical bone loss less than 0.2 mm annually following 
the implant’s first year of service; 4) individual implant performance to be 
characterized by an absence of persistent and irreversible signs and symptoms such as 
pain, infections, neuropathies, paresthesia, or violation of the mandibular canal; 5) 
success rate of 85% at the end of a five-year observation period and 80% at the end of 
a ten-year period to be the minimum criterion for success” (Albrektsson et al., 1986). 
These are practical and easy to use in assessment of dental implants. 
More recently, criteria for implants were approved by The American Academy of 
Periodontology in 2000 (Iacono, 2000). These include: “1) absence of persistent 
signs/symptoms such as pain, infection, neuropathies, parathesias, and violation of 
vital structures; 2) implant immobility; 3) no continuous peri-implant radiolucency; 4) 
negligible progressive bone loss (less than 0.2 mm annually) after physiologic 
remodeling during the first year of function; 5) patient/dentist satisfaction with the 
implant-supported restoration” (Iacono, 2000). These are clear and concise criteria. 
4.2 Cumulative success rates. Implant cumulative success rates are usually evaluated 
in years categorized as less than 5 years (short run), from 5 to 10 years (intermediate 
run), and greater than 10 years (long run) (Smith and Zarb, 1989). Cumulative success 
rates of dental implants are affected by many factors. These include implant location 
in the upper or lower jaw and its position in the dental arch, implant type, diameter 
and length, prosthetic construction, and whether they are used for single tooth 
replacement or in an edentulous month (O'Roark, 1991). Cumulative success rates of 
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dental implants have been tabulated according to life in service, mandibular or 
maxillary location, and use as a single replacement or in an edentulous month (Table 
2). 
Table 2: Cumulative success rates for dental implants 
 General Mandible Maxilla Single1 Edentulous 
?5 years 95.4%2 98.2%3 97.3%3 98.3%4 93.9%5
5-10 years 92.2%2 93%6 88%6 97.4%7 88.3%8
> 10 years 87%9 91%10 81%10 89%11 no reported 
1Single = Single implant prostheses; 2Brocard et al., 2000; 3Buser et al., 1997; 4Buser 
et al., 2002; 5Higuchi et al., 1995; 6O'Roark, 1997; 7Priest, 1999; 8Zarb and Schmitt, 
1991; 9Keller et al., 1999; 10Adell et al., 1985; 11Walther et al., 1996. 
It can be concluded that, due to their high success rates, dental implants constitute a 
remarkable improvement in modern dentistry. At the end of 10 years in service, a 
similar cumulative success rate has been found for different dental implants in a 3000-
implant study; Rates were 88% for maxillary and 93% for mandibular implants, which 
covered a 25-year observation period (O'Roark, 1997). It has been calculated that in 
Finland about 52 to 55% of a total of 17,785 dental implants have been performed in 
patients whose mean age is 49.5 years (range, 40 to 59) (Pihakari et al., 1999). Thus, 
many patients will be about 60 years or older when their implants fail more than 10 
years after implantation. Among these failure patients, some require revision 
operations. In other patients, general and local contra-indications may restrict the 
possibilities for re-implantation (Oikarinen et al., 1995). It would therefore be 
beneficial if dental implants would last for a lifetime. 
A huge number of dental implantations have been performed worldwide. The 
Brånemark osseointegration implant system has been used more than 600,000 times 
during the last 30 years (Clapp et al., 1996). In the USA alone, it has been estimated 
that more than 300,000 dental implants are performed annually (Parker and Miller, 
1989; Klinger et al., 1998). According to a recent report, those actually implanted in 
the USA in 2000 numbered 910,000 (Annual Industry Report, 2000). The number of 
patients who suffer from failures would therefore be high, although implant failure 
rates are quite low. The main symptom of loosening is a gradually increasing mobility 
associated with pain, especially when masticating (Buchs et al., 1996). 
Unfortunately, there are no reliable surveys reporting how many dental implants will 
be required in the future. The revenue of the European dental implant market by 2006 
has been predicted to reach $269.8 million (Millennium Research Group, 2002). The 
compound annual growth rate of the Japanese dental implant market from 2002 to 
2006 has been estimated to be 9.4% (The Japanese market for dental implants, 2002). 
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Because of the growing demand for dental implants, their failure is becoming one of 
the most challenging dental complications of our times (Duyck and Naert, 1998; 
Esposito et al., 1998; el Askary et al., 1999). 
The first nine implantations performed by a novice dentist have been reported to fail 
(Lambert et al., 1997). Failure rates even as high as 38.5% for some dentists were 
reported a decade ago (Owall et al., 1992). However, with improvements in dental 
implantation skills and equipment, it is possible to diminish the failure rates in the 
future. 
5. FAILURE OF DENTAL IMPLANTS
5.1 Failure types. Failure is a condition or instance of not functioning or not 
functioning adequately (Koenisberger, 1998). In 1978, the NIH recommended the 
following criteria for removal of a dental implant: “1) chronic pain; 2) significant 
movement; 3) infection; 4) significant progressive loss of supportive bone; 5) 
intolerable dysthesia (anesthesia or parasthesia); 6) oro-antral or oro-nasal fistulae; 7) 
bone fracture; 8) psychological or other significant medical problems; 9) 
uncorrectable implant breakdown; 10) possible irreversible damage to adjacent teeth; 
11) cosmetic problems” (Dental Implants, NIH Consensus Statement, 1978). 
Generally, early- and late-stage failures can be distinguished in terms of 
osseointegration. 
5.1.1 Early-stage failure. Early-stage failure refers to a failure to establish 
osseointegration before loading; the failure rate was about 3.6% in a 16,935-implant 
study (Esposito et al., 1998a), in which the main reasons were suggested to be 
surgical trauma leading to impaired wound healing, premature loading, and infection 
(Esposito et al., 1998). 
5.1.2 Late-stage failure. Late-stage failure is defined as a failure to maintain the 
achieved osseointegration after loading (Esposito et al., 1998). From the point of view 
of loading time and mechanism, late-stage failure can further be divided into 
mechanical and biological late-stage failure. 
5.1.2.1 Mechanical late-stage failure. Mechanical late-stage failure rates are high 
within the first 4 months (120 days), that is, during the early post-implantation period 
(Tonetti, 1998). They comprise implant fractures, abutment screw fracture, and 
mechanical retention problems of over-denture (Goodacre et al., 1999). Implant 
fractures usually involve the framework, veneering material, and opposing prosthesis. 
The mechanical failure rate has been calculated to be about 1.4% (Brocard et al.,
2000). The two-stage external hex screw-type implants have been reported to fail at a 
rate of about 8.7% (Schwarz, 2000). Mechanical complications have shown a 
tendency to decline (Eckert et al., 2000). 
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5.1.2.2 Biological late-stage failure (loosening). The main reasons for loosening are 
chronic infection (implant plaque) and overload, together with host characteristics 
which result in adverse tissue responses (Esposito et al., 1998; Santavirta et al., 1999). 
Loosening is a result of marginal infection and bio-mechanical overload or a 
combination of these two factors (Tonetti and Schmid, 1994). Some of the late-stage 
loosening is caused by metal fatigue fractures (Hoyer et al., 2001). 
5.2 Cumulative failure rates. Failure rates and reasons for failure have been less 
intensively investigated than the success rates. Many factors affect implant failure 
rates. They may be related to implant type and location in mandible or maxilla, use as 
a single tooth replacement or in an edentulous mouth (Duyck and Naert 1998; 
Pihakari et al., 1999). Some examples of implant failure rates are listed in Table 3. 
Table 3: Examples of cumulative failure rates 
General Mandible Maxilla 
Single 
implant 
prostheses Edentulous 
Early-stage failure 3.4%1 3.6%1 5.3%1 1%2 6%1
Late-stage failure (<5years) 4.6%3 4%4 7.5%4 1.3%5 9.2%6
Late-stage failure (5-9 years) 6.6%3 4.3%7 11.3%4 2.4%8 14%9
Late-stage failure (?10 years) 7.4%1 7%4 12%4 2.6%10 no 
reported 
1Snauwaert et al., 2000; 2Jemt et al. 1990; 3Brocard et al., 2000; 4O'Roark, 1997; 
5Testori et al., 2000; 6Hutton et al., 1995; 7Tinsley et al., 1999; 8Malevez et al., 1996; 
9Adell et al., 1985; 10Priest, 1999. 
It can be concluded that implant failure rates are quite low with late-stage failure 
found to explain about 50% of all failures (Pihakari et al., 1999). The proportion of 
late failure rates will increase with the improvement of implant materials and designs 
(which will reduce mechanical failures) and surgical technologies (which will also 
reduce early-stage failures). The major problem in implant dentistry in the future will 
therefore become late-stage failure or loosening (Esposito et al., 1998). Loosening 
means a mode of failure resulting from implant movement or migration in the bone 
(or in case of cemented implants, in the cement) (Franz, 1997). 
6. THE CONCEPT OF LOOSENING
Loosening may be defined as the end result of adverse biological host responses 
combined with cyclic occlusal loading and growth of bacterial pathogens in the peri-
implant pocket and/or plaque (Gross, 1988; Swanberg and Henry, 1995; Leonhardt et 
al., 1999). Clinically, loosening can be defined as increasing mobility of the implant 
associated with pain (Dental Implants, NIH Consensus Statement, 1978; Piattelli et
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al., 1998a). Radiologically, loosening is characterized by loss of peri-implant crestal 
bone (Engquist et al., 1988). 
7. WHY DO DENTAL IMPLANTS LOOSEN/ FAIL?
This is a very complicated question, which needs to be clarified in the future. Of the 
many risk factors found to affect the failure process directly or indirectly (Duyck and 
Naert, 1998; Esposito et al., 1998; el Askary et al., 1999), some are listed in Table 4, 
and their associations with various loosening patterns. These risk factors can be 
grouped into three categories, namely dentist-, implant-, and host-related risk factors. 
7.1 Dentist-related risk factors
7.1.1 Preoperative factors. Clinical radiographic techniques are routinely used before 
implant dentistry is planned (Verhoeven and Cune, 2000). Radiographs are used to 
check the quantity and quality of the implant bone beds and their relation to 
surrounding structures such as the mandibular canal and maxillary sinus (Dula et al.,
2001). Methods used include periapical X-rays, the panoramic X-ray, computed 
tomography, and magnetic resonance imaging (Butterfield et al., 1997). It has been 
reported that intraoral X-rays are associated with an approximately 14% 
magnification (Lazzerini et al., 1996), and panoramic images have been increased 
approximately 25% in size (Reddy et al., 1994). X-ray magnifications may thus lead 
to mistakes in planning and in performance of dental implantations, making special 
methods necessary to correct for eventual magnification which will enable recording 
of exact anatomical measurements. 
7.1.2 Peroperative factors. Overheat which is produced by friction from high torque 
equipment damages the implant bone bed and contributes to early-stage failure of 
implants (Piattelli et al., 1998b). About 3.6% of implant failures have been estimated 
to be related to surgical trauma (Esposito et al., 1998). Secondly, a nonideal position 
for the dental implant may subject it to non-axial loading during mastication. This 
increases risk for implant fractures and peri-implant bone fractures, which usually 
occurs in the posterior region that is subjected to a high load, in particular if the 
patient has comparatively low bone density in this region (Kerstein, 2001). Hollow 
implants lead to increased implant fracture rates if the implant is too small in 
diameter. This usually happens with the use of two-stage external hex screw-type 
implant systems (Piattelli et al., 1998c). Selection of too-short implants may also 
increase the failure rate. 
7.1.3 Postoperative factors. Improper design and guidance of the crown contribute to 
failure. Too high a cusp or too high an occlusal alignment can increase occlusal 
loading to an unacceptable level (Reitz, 1994; Gittelson, 2002). The crown can also 
contribute to too-wide contact between the counter tooth and the implant, which leads 
to high occlusal load of the implant in bone. Occlusal forces contribute to implant 
fractures and peri-implant bone fractures. Crown width, cusp height, guidance, and 
occlusal alignment can all be used to control occlusal forces (Weinberg et al., 1988). 
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Currently, a T-scan occlusal analysis system provides one option to assess occlusal 
forces (Chapman and Kirsch, 1990). The T-Scan system is a computerized dental 
device which can quantitatively analyze occlusal contacts (position, strength, and 
frequency of occlusal contacts). 
Ideally, occlusal loading should be distributed to peri-implant bone though the long 
axis of the implant. The more the lateral loading and non-axial forces can be reduced, 
the better (Kaukinen et al., 1996; Reitz, 1994). If this does not succeed, occlusal 
loading will be focused on the abutment neck area of the peri-implant bone. This has 
been confirmed by use of finite element analysis for biomechanical modeling 
(O'Mahony et al., 2000). Excessive loading leads to multiple complications, which 
can lead to loosening of the implant or to implant abutment fractures. In terms of 
implant bone bed, it may lead to bone microfractures and marginal or periapical bone 
loss (Piattelli et al., 1998b). Therefore, improper implant restoration may lead to 
implant failure, but peri-implant bone loss can be associated even with properly fixed 
implants, which will be discussed in biological occlusal loading (7.3.1.1). 
In short, any improper decision increases the risk of failure. As a result of the 
development of clinical implantology in the past half century, these kinds of failures 
are relatively few now and will become even less frequent in the future (Albrektsson, 
2001). From the viewpoint of prevention, however, clinical dentists should pay close 
attention to all steps during implant treatments. 
7.2 Implant material-related risk factors
7.2.1 Dental implant material characteristics. The ideal dental implant material should 
be “1) biocompatible (Santavirta et al., 1991; Edgerton and Levine, 1993), 2) of 
appropriate rigidity for prosthetic function, 3) intimately adaptable to both bone and 
gingiva surrounding the implant, 4) functionally able to dissipate forces resulting from 
occlusal load on the prostheses supported by the implant to the underlying bone, 5) 
resistant to the large and diverse peri-implant microbial load” (LeGeros and Craig, 
1993). 
In fact, none of the dental implants meets all these characteristics. Biocompatibility, 
one of the most important factors, means the ability of the implant to elicit an 
appropriate host response in its specific application (Edgerton and Levine, 1993). Use 
of bioincompatible implant materials leads to implant failure initiated by adverse host 
tissue responses (Santavirta et al., 1999). Multiple coating technologies have been 
developed to improve implant biocompatibility at the host-implant interfaces 
(Aspenberg et al., 1996). These coatings comprise titanium oxide (TiO2) coating, 
ceramic coating, or diamond coating (Aspenberg et al., 1996; Santavirta, 2003). 
Biodegradable ceramic coating may have the best future prospects. 
Most dental implant materials presently used in clinics are quite biocompatible in 
human tissues in their specific dental application. They are usually made of titanium, 
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Table 4: Some risk factors for implant failure and the most commonly associated failure patterns 
Risk factor    Suggested mechanism of action      Failure pattern 
Improper patient selection  Not enough bone, peri-implant bone fractures    Early failure 
Improper material/design  Implant fracture, metal fatigue      Early, intermediate, or late failure 
Improper implant or abutment size Implant fracture       Early or intermediate failure 
Overloading    Greatly increased mechanically induced bone resorption   Early or intermediate failure 
Overheat    Bone-bed destruction, poor healing     Early failure 
Parafunctional habits   Increased mechanically induced bone resorption or bone fracture  Early or intermediate failure 
Systemic factors   Impaired bone quality (osteoporosis, osteomalacia)   Intermediate or late loosening 
Medication    Impaired bone quality       Intermediate or late loosening 
Occlusal loading   Moderately mechanically induced bone resorption   Late loosening 
Poor oral hygiene   Pathogen bacteria/plaque induced pathological bone resorption  Intermediate or late loosening 
Biocompatibility of implant surface Adverse host tissue responses       Late loosening 
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titanium-aluminum-vanadium (Ti-6Al-4V), cobalt-chromium-molybdenum and more 
rarely of other alloys (Lacefield, 1988). Their use is evidence-based and supported by 
their good success rates (Adell et al., 1981). 
7.2.2. Implant surface. The dental implant surface can be separated into the collar area 
and non-collar area. Smooth surfaces are favored for collar areas to reduce bacteria 
adhesion and to reduce subsequent peri-implantitis. In contrast, a smooth surface 
reduces the degree of osseointegration of the non-collar (root) area (Wiskott et al., 
1999), whereas rough or porous implant surfaces improve osseointegration 
(Lumbikanonda et al., 2001). Rough surfaces also enhance osteoblast adhesion (Noth 
et al., 1999). Unfortunately, these requirements are in conflict with each other at the 
transition of the root to collar area. This conflict cannot yet be completely solved, 
which means that the risk for failure of dental implants will rise. 
3) Interface tissue. There are three kinds of connections between dental implants and 
host bone (Craig and LeGeros, 1999). 1) The direct bone and implant connection, 
which is called osseointegration (Brånemark et al., 1977), 2) Fibro-osseous 
integration, which is mediated by an intervening fibrous tissue layer approximately 
100 micrometers thick (Weiss, 1986; Ko et al., 1992; Piattelli et al., 1998a), 3) 
Periodontal connective tissue-like attachment which is found, it seems, very rarely, 
and refers to the periodontal ligament-like organization of peri-implant collagen fibers 
(Takata et al., 1993; Choi, 2000) or to cementum formation on endosseous dental 
implants in some cases (Guarnieri et al., 2002). 
Fibro-osseous integration, indicating the presence of a thin fibrous interface tissue, is 
the most frequently seen mode of attachment among these three different types of 
connections. Interface tissue is a result of implant wound healing, with multiple 
components of the extracellular matrix identified in this fibrous interface tissue (Table 
3). Type I and III collagens in the interface tissue reflect the stability of the implant 
capsule (von Recum et al., 1993). Cellular fibronectin has been found and probably 
plays a role in the direct attachment of the fibrous interface to the implant surface 
(Bagambisa et al., 1994). 
In summary, dental implant materials have been remarkably improved in the past half 
century to meet all kinds of demands. However, research and development are needed 
to develop even more biocompatible and functional materials to prevent implant 
failures and to prolong implant life in service. 
7.3 Host-related factors. Dental implants are located in the oral cavity, peri-implant 
soft tissues, and host bone, which means that microbes and host-related factors affect 
the outcome. Host-related factors can be divided into local and systemic risk 
(prognostic) factors. As we studied proteolytic enzymes as markers and mediators of 
biological late-stage loosening, they are in the main issue of this review of host-
related factors of significance for implant success. 
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7.3.1. Local risk factors
7.3.1.1 Biomechanical occlusal loading. Even well-performed and optimally 
occlusally restored dental implants tend to lead to peri-implant bone loss. In order to 
review this in more detail, dental implants will be compared with natural teeth. 
Three functional hypotheses aim to explain how periodontal ligament tissue supports 
the tooth during high occlusal force. 1) Periodontal ligament tissue is a tensional 
support tissue (Mühlemann, 1967). Collagens, in particular the interstitial collagens 
type I and III, provide tensile strength in the human body and are the main collagens 
in the periodontal ligament (Persikov and Brodsky, 2002). About 10% of the collagen 
in the periodontal ligament is remodeled every day, which makes this site the most 
rapidly remodeling of all tissues in the human body (Laurent, 1987). This indicates 
that collagen in the periodontal ligament ages very rapidly under high occlusal 
loading, and means that the structural integrity of the periodontal collagen is 
compromised but maintained by high remodeling. 2) Periodontal ligament tissue 
forms a viscoelastic system, and the impact load of occlusal forces is balanced by a 
viscoelastic cushion effect. When squeezed under loading, the periodontal ligament 
slowly releases fluid into the tissues and blood and lymphatic vascular system, thus 
absorbing the energy of the impact (Picton and Wills, 1978). 3) The periodontal 
ligament is part of a stomatognathic complex, which is a stress feedback pathway 
(Lund, 1991). Masticatory muscles are controlled by sensory input which activates 
negative feedback to avoid excessive loading of one or several teeth (Linden and 
Millar, 1988). These three periodontal ligament functions can together effectively 
control even high occlusal load, which could not safely be distributed to the alveolar 
bone socket of the teeth. Tooth movements correlate with occlusal forces, although 
there occurs only a little tooth displacement even under a high load (Figure 2A). 
Clearly, the interface tissue between the dental implant and its bone bed can hardly 
distribute the tension to peri-implant support tissue as effectively as does the 
periodontal ligament. The eventual function of the interface tissue as a viscoelastic 
shock-absorbing cushion has not been studied. Dental implants lack the stress 
receptors located in the tensional periodontal ligament tissue in natural teeth, and their 
stomatognathic sensor system is less sensitive than that of healthy teeth (Klineberg 
and Murray, 1999; Jacobs and van Steenberghe, 1991; Jacobs and van Steenberghe, 
1993). Therefore, due to non-optimal load protection and force-absorbing and -
distributing systems, a dental implant is subjected to implant micromotion ranging 
from 50 to 150 micrometers (Szmukler-Moncler et al., 1998). Implant micromotions 
are defined as recoverable displacements of the implant that occur during a finite 
period of loading. Horizontal movement of the maxillary central incisor ranges 
between 0 and 200 ?m (Mühlemann, 1967), so the maximal micromotion of a dental 
implant is less than that of a natural tooth. It has been concluded that occlusal loading 
strains the hard peri-implant bone, because implants lack the protective periodontal 
ligament system. The relationship of displacement and implant loading continues to 
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be almost linear, without a smoothing or break in the curve after the first moving 
stage as is seen in natural teeth (Figure 2). 
Figure 2. (A) Load-displacement curve of a maxillary incisor tooth in a Rhesus 
monkey model (Mühlemann, 1967). (B) Load-displacement curve of implant in a 
sheep tibial bone model. The TiO2-coated titanium implant was used at a diameter of 
3.5 mm (Soncini et al., 2002). 
High mechanical loading leads to increased bone resorption. Osteocytes increase their 
collagenase-1 (MMP-1) production under mechanical load, which may initiate bone 
resorption (Redlich et al., 2001; Holliday et al., 1997). MMP-1 degrades bone type I 
and III collagens, the main structural collagen of bone (Rubin et al, 1999). Tartrate-
resistant acid phosphatase and cathepsin K increase in osteoclasts during 
mechanically induced bone resorption (Kurata et al., 2001). According to one study, 
peri-implant vertical bone loss in the maxilla is 0.2 ± 0.3 mm per year for Astra Tech 
implants and 0.2 ± 0.1 mm for Brånemark implants. The corresponding figures in the 
mandible are 0.3 ± 0.2 mm and 0.2 ± 0.1 mm, respectively (Engquist et al., 2002). In 
another study, about 1 to 1.5 mm bone was lost during in the first year, followed by 
0.2 mm in subsequent years for a two-stage Brånemark type implant (Adell et al., 
1981; Albrektsson et al., 1986). Less than 0.2 mm annual bone loss was thus 
suggested as an implant success criterion in dental implantology (Albrektsson et al., 
1986). This, however, is more than about 0.1 mm of vertical bone loss, which occurs 
annually in the healthy adult periodontium (Hugoson et al., 2000). The annual 
alveolar bone loss was found to vary between 0.07 and 0.14 mm at ages between 25 
and 65 years (Papapanou, 1989). The annual rate of peri-implant bone loss is thus 
about twice as fast as that occurring around the healthy normal tooth. Different 
occlusal loading in different areas of the jaw can in part explain why implant success 
rate is related to implant location (Drago et al., 1992). 
It can be concluded that the enhanced peri-implant bone loss is related to the normal 
occlusal loading to which the implant is subjected. Although the shortcomings of 
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dental implants in comparison to natural teeth may never be overcome, dental 
implants are still a good choice compared to some other conventional prosthetic 
treatments. 
7.3.1.2 Peri-implantitis and clinical indices. Poor oral hygiene and a rough implant 
surface contribute to the formation of bacterial plaque (Figure 3). To improve implant 
longevity, a rough implant surface which increases plaque formation at the collar area 
should be avoided (Grossner-Schreiber et al., 2001). Micro-gaps between various 
implant components favor bacterial adhesion and colonization. They are usually 
located in the implant-transmucosal abutment interface, transmucosal abutment-
prosthesis interface, and implant-prosthesis interface (O'Mahony et al., 2000a). Oral 
hygiene and professional implant maintenance are strongly recommended 
(Springstead et al., 1993). 
More than 300 bacterial microorganisms have been discovered in the infected implant 
plaque. Porphyromonas gingivalis, Bacteroides forsythus, Fusobacterium nucleatum,
Campylobacter gracilis, Streptococcus intermedius, and Peptostreptococcus micros
are clearly related to peri-implantitis (Kalykakis et al., 1998; Leonhardt et al., 1999). 
Bacteria produce bacterial collagenases, which have been shown to cleave gingival 
collagen (Mailman, 1979; Harrington, 1996). Even more importantly, bacterial 
components may stimulate the peri-implant host cells to produce collagenases and 
osteoclast-activating cytokines. Osteoclasts resorb peri-implant bone and lead to 
vertical peri-implant bone loss. 
Dental plaque with its bacteria is probably the main pathogenetic factor in chronic 
periodontitis and peri-implantitis (Watts, 1996). Pathogenic bacteria can induce 
resident host cells to produce or release proteinases or to both, which contributes to 
periodontal tissue destruction (Teronen et al., 1997). Pathogenic bacteria can increase 
proteinase levels by several mechanisms. Bacteria may be chemotactic, leading to 
leukocyte accumulation (Miller et al., 1975). Upon phagocytosis, polymorphonuclear 
leukocytes release MMPs and other hydrolytic enzymes (Ding et al., 1997). Bacterial 
membrane components can induce polymorphonuclear leukocytes to produce MMPs 
(Ding et al., 1996). Bacterial proteinases can convert proMMPs into their active 
counterparts, which may be a rate-limiting step during tissue degradation (Okamoto et
al., 1997; Sorsa et al., 1992). 
Chronic periodontitis is an inflammatory process characterized by increased pocket 
probing depth, bleeding on probing, and increasing tooth mobility (O'Reilly and 
Claffey, 1996). Many clinical indices have been introduced in order to grade the 
degree of inflammation in periodontitis. These include plaque index (Silness and Loë, 
1964), periodontal index (Russell, 1967), periodontal disease index (Ramfjord, 1967), 
and gingival index (Löe, 1967). 
26  
Peri-implant gingival mucosa around dental implants is composed of keratinized oral 
epithelium covering a connective tissue matrix. Its molecular composition, including 
collagen, cells, and vascular structures, is almost identical to that of healthy tooth 
gingival mucosa. However, the thickness of the entire gingival soft tissue and of the 
keratin layer in peri-implant mucosa was found to be 34% and 50% thinner, 
respectively, than in healthy mucosa (Lindhe and Berglundh, 1998). As a result of 
these circumstances, all kinds of products from the oral cavity and peri-implant pocket 
easily penetrate the peri-implant mucosa. This may be the reason for the presence of 
very high numbers of inflammatory cells around loosened dental implants (Liljenberg
et al., 1996). 
Peri-implantitis is also an inflammatory process which shares some of its features 
with chronic periodontitis (Meffert, 1996). Some of the periodontal indices have been 
modified to be applied in peri-implantitis in order to quantify the degree of 
inflammation (Mombelli et al., 1987). Modified gingival index and bleeding on 
probing, suggested as diagnostic markers of peri-implantitis, are also good markers 
for clinical follow-up of implant treatments (Mombelli et al., 1987; Luterbacher et al.,
2000). 
7.3.1.3 Cigarette smoking. In the USA in 1997, about 924 million packs of cigarettes 
were consumed by 12- to 17-year-old youth alone. Each day in the USA, the number 
of smokers of this age equals approximately 3.76 million (DiFranza and Librett, 
1999). In Finland in 2000, nearly 0.34 million workers were subjected to 
environmental tobacco smoke at work, representing 16% of the employed population. 
Although smoking indoors is forbidden by Finnish law, 0.6 million Finns (1% of the 
population) were surprisingly found to suffer from indirect smoking at home 
(Kauppinen and Virtanen, 2002). 
Nicotine, a major component of tobacco, inhibits collagen production by gingival 
fibroblasts and enhances collagen breakdown (Tipton et al., 1995). Nicotine is 
cytotoxic to periodontal ligament cells and inhibits their growth (Alpar et al., 1998; 
James et al., 1999). It prevents differentiation of osteoblast-like cells to osteoblasts 
(Nociti et al., 2002) and reduces alveolar bone quality (Yuhara et al., 1999). Serum 
nicotine levels correlate with severity of periodontal attachment loss (Gonzalez et al., 
1996). In a series of 12,329 periodontitis-affected patients in the USA, smoking was 
identified as a risk factor in more than 50% (Tomar and Asma, 2000; Wallace, 2000). 
Smoking has also been linked to the loosening of dental implants (Schwartz-Arad et 
al., 2002). 
7.3.1.4 Para-functional habits, bruxism. Para-functional habits and bruxism are very 
common occlusal diseases. Heavy occlusal forces constitute a risk factor for loosening 
of dental implants. Metal fatigue and implant fractures occur more frequently in these 
patients than in controls. More than 77% of all implant fractures have been reported to 
occur in patients who have signs and a history of chronic bruxism (Rangert, 1994). 
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Para-functional habits are related to increased peri-implant bone loss (Engel et al., 
2001). Attention should be paid to para-functional habits when decisions on dental 
implantation are made (Misch, 2002). 
7.3.2 Systemic factors. Systemic factors affect both the quality and quantity of bone, 
which constitute important prognostic factors for dental implant survival. These 
systemic factors comprise poorly controlled diabetes, osteoporosis, osteomalacia, 
irradiation, and medications (Roberts et al, 1992). 
7.3.2.1 Diabetes mellitus. Diabetes mellitus, a common disease, was in the USA in 
1998 the fifth most common disease leading to death (Guyer et al., 2000). The 
incidence rate of diabetes mellitus in Finland during 1989-1994 was 0.402/1000 
annually, which is high compared to the average normal rate (0.032/1000) (Patterson 
et al., 2001). About 10% of all Canadians are currently found to suffer from diabetes, 
which is a risk factor for periodontal diseases (Matthews et al., 2002). 
Diabetic lesions involve bone, gingival, and vascular tissues (Johnson, 1992). This 
disease is thought to suppress collagen synthesis (Schneir et al., 1979; Spanheimer et
al., 1988), and it increases the expression of MMPs. The levels of MMP-8 and 
MMM-9 activities in saliva correlate with clinical periodontal findings such as 
gingival bleeding and pocket depth (Collin et al., 2000). MMP-8 and MMP-9 act 
cooperatively in degradation of type I collagen in gingival and bone tissues. These 
conclusions have been confirmed in a rat model (Golub et al., 1978). Although most 
studies of diabetic lesions have been focused on periodontitis, diabetes mellitus has 
also been considered a risk factor and occasionally even a contraindication for 
performing dental implantations. Recently, it has been reported that dental implants in 
diabetes are successful, at least in the short term (Olson et al., 2000). 
7.3.3.2 Osteoporosis. Osteoporosis is a very common disease, with the number of 
elderly people affected only in Europe, Japan, and the USA being 75 million (South-
Paul, 2001). Two million cases of bone fractures have been annually found in the 
USA to be associated with osteoporosis (Riggs et al., 1988). 
The main pathological features of osteoporosis are low bone mass and a 
microarchitectural deterioration of bone leading to fragility, and thence to an 
increased fracture risk. The multiple pathogenic factors related to osteoporosis 
comprise genetic predisposition and subtle alterations in systemic and local hormones, 
together with environmental influences (Lazner et al., 1999). Currently research 
interest is focused on the role of cathepsin K in the degradation of bone matrix in 
osteoporosis (Lazner et al., 1999). 
Both the maxilla and mandible can be affected by osteoporosis, which has been 
considered a risk factor for implant failures and periodontal diseases. The local bone 
quality of the implantation bed is a more sensitive prognostic factor in this respect 
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than that of peripheral bone in general in osteoporosis patients (Becker et al., 2000). 
Implants in osteoporosis have been successful in the short term, but long-term results 
have not been reported (Eder and Watzek, 1999). 
7.3.3.3 Medication and irradiation therapy. Some medications widely used in clinics 
cause bone loss. In particular, glucocorticosteroids cause iatrogenic osteoporosis by 
increasing bone resorption via stimulation of osteoclastogenesis (Canalis and Delany, 
2002). 
Other drugs with deleterious effects on bone include chemotherapeutic agents such as 
doxorubicin and methotrexate, which inhibit osteoblasts and diminish bone formation 
(Friedlaender et al., 1984). Implants are often used in cancer-surgery patients. In oral 
cancer patients, however, tumor resection is usually combined with irradiation, which 
locally impairs bone quality and impairs the prognosis of dental implants in the long-
term. In one study, irradiation had no effect on implant success rate in the short term 
(Jisander et al., 1997), whereas another study found implant survival to be lower 
(Visch et al., 2002). 
Figure 3. Some dentist-, host-, and implant-related risk factors contributing to adverse 
host responses and pathological destruction of peri-implant tissue. 
In summary, loosening of dental implants is a complicated process affected by many 
host-related risk factors. To completely understand the loosening process, a huge 
number of implants in different clinical situations are required for analysis. One 
pioneering nationwide project started in Finland in 1994 with the aim to record all 
implanted and loosened needing removal dental implants in the whole country. It has 
already collected and published much valuable information (Pihakari et al., 1999). 
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Some of the risk factors overlap with each other and affect the loosening process 
independently or cooperatively (Figure 3). However, no matter the type of risk factor, 
they eventually contribute to peri-implant tissue destruction. The main pathological 
feature of loosening is a progressive loss of peri-implant support tissue as a result of 
adverse host tissue responses (Tonetti and Schmid, 1994; Duyck and Naert, 1998; 
Santavirta et al., 1999). 
8. ADVERSE HOST RESPONSES DURING LOOSENING
8.1 Host responses and their types
Response is a basic concept in medicine, which means any organic process elicited by 
a stimulus (Koenisberger, 1998). Generally, host responses are grouped into 
inflammation, foreign body reactions, immunological and toxicological reactions, and 
tumorigenesis. 
Two kinds of interactions exist between dental implants and their host tissues. Host 
tissues affect implant materials, which can for example become corroded (Voitik, 
1996). On the other hand, implantation and implant materials induce various kinds of 
tissue reactions such as wound healing, inflammation, foreign-body reactions, and 
fibrosis (von Recum et al., 1993; Meffert, 1996; Konttinen et al., 2001). What type of 
tissue response is elicited is determined by the degree of biocompatibility of the 
implant material. Biocompatibility means the capability of a prosthesis implanted in 
the body to exist in harmony with tissue without causing deleterious changes such as 
fibrous capsule formation, wear, and infection (Koenisberger, 1998). The more 
biocompatible are the implant materials applied, the fewer adverse host tissue 
responses will follow. 
Unfortunately, no completely biocompatible implant material has yet been found. 
Non-biocompatible materials have been considered to exert adverse effects in 
loosening of hip implants (Edgerton and Levine, 1993; Santavirta et al., 1999). 
Development of more biocompatible implants or coating materials is one of the main 
directions of current research. For example, diamond-coated implants have been 
developed for joint replacement and dental implantology in Finland (Aspenberg et al.,
1996; Santavirta et al., 1999). 
Special attention was in this study paid to host tissue responses, which induce a rise in 
various proteinases and osteoclast-activating cytokines, leading to destruction of 
extracellular matrix (collagen, cellular fibronectin, and bone) in the peri-implant 
support tissue. Knowledge of the relationship between implants and host tissue 
responses may lead to the development of future diagnostic markers. Their use may 
allow us to monitor the progression of loosening, which will be helpful in its 
prevention and treatment. 
8.2 Extracellular matrix
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8.2.1 Collagens. Collagens are the most abundant extracellular proteins in man, with 
20 different types of collagens identified (Persikov and Brodsky, 2002). Collagens are 
composed of hundreds of amino acids, and glycine is located at every repeating Gly-
X-Y triplet amino acid sequence. These amino acid triplets form a single ? chain, 
which is the smallest structural unit of collagen. Three ?-chains form a triple helical 
collagen monomer. These collagen monomers align into a nearly three-quarter-
overlapping collagen fiber, which is stabilized through intermolecular cross-links. 
These fibers are then organized into collagen bundles and networks in tissues 
(Persikov and Brodsky, 2002). 
Collagens are relatively resistant to proteolysis by nonspecific proteinases because of 
their covalently cross-linked triple helical and fibrillar structure (Welgus et al., 1981). 
Collagens maintain the structural integrity of human tissues and provide mechanical 
support and tensile strength (Mechanic et al., 1974). The proportions of type I and III 
collagens in various peri-implant and periodontal tissues are listed in Table 5. The key 
question in understanding chronic periodontitis relates to pathological proteolysis of 
type I and III collagens. 
Table 5. Extracellular components in tooth and implant support tissues 
Collagen type I type III Other components 
Gingiva 80-85%1 < 3%1 Fibronectin, laminin, tenascin, 6% elastin 
Periodontal 
ligament 
84%2 15%3 Collagen V, VI, VII < 1%3, glycoproteins, 
elastin 
Interface 
tissue 
found4 found4 Fibronectin, laminin, tenascin-X, tenascin-C5
Root 
cementum 
90%6 < 5%6 Bone sialoprotein, osteocalcin, osteopontin 
Alveolar 
bone 
95%8 very little7 5% noncollagenous proteins (osteocalcin; 
osteonectin)8
1Schroeder and Page, 1990; 2Butler et al., 1975; 3Delaisse and Vaes, 1992; 4von 
Recum et al., 1993; 5Li, 2000b; 6Birkedal-Hansen et al., 1977; 7Ross et al., 1995; 
8Freeman, 1994. 
8.2.2 Fibronectin and integrins. Fibronectin is one of the major noncollagenous 
proteins and is found in small amounts in periodontal tissues (Bartold et al., 1998) 
(Table 5). Two types of fibronectin have been identified: One is plasma fibronectin, 
the soluble form of fibronectin plasma produced by hepatocytes (Tressel et al., 1991). 
The other form is cellular fibronectin, which occurs in most tissues (Vartio et al.,
1987). Cellular fibronectin is expressed by tissue fibroblasts, epithelial cells, and 
macrophages (Vartio et al., 1987). Fibronectin is a dimer composed of two similar but 
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not completely identical chains. Cellular fibronectin acts as a bridge-like link between 
cells and collagen matrix and has been shown to be a substrate for cell adhesion 
(McDonald and Kelley, 1980; Bartold et al., 1998). 
The extracellular matrices mainly affect the cells through cellular receptors known as 
integrins (Mohri, 1996). Integrins are heterodimeric glycoproteins composed of ? and 
? subunits. Thus far, 15 different ? chains have been identified; the corresponding 
number for ? subunits is eight. 
8.2.3 Bone 
Bone is connective tissue, which is composed of calcified extracellular matrix and 
bone cells (Gartner and Hiatt, 1997). The organic portion is composed of collagen 
fibers (type I collagen) and ground substance (keratan sulfate, chondroitin sulfate, 
hyaluronic acid) (Batge et al., 1992). The inorganic portion accounts for about 65% of 
the dry weight of the bone. Type I collagen fibers are embedded in a complex of 
calcium and phosphate which forms hydroxyapatite [Ca10(PO4)6(OH)2] (Schroeder 
and Page, 1990). 
Osteoblasts, which originate from periosteum and endosteum, are located on the 
external surface of bone or of the internal surface of the bone adjacent to the bone 
marrow. They secrete and deposit collagen type I and non-collagenous proteins 
around themselves. These kinds of osteoblasts turn into osteocytes when they become 
embedded in bone (Gartner and Hiatt, 1997). In mature bone, osteocytes occupy 
lacunae in the solid and mineralized bone matrix and communicate with each other 
through their cytoplasmic extensions located in bone canaliculi. 
Osteoclasts are multinucleated giant cells containing multiple vacuoles and lysosomes 
(Blair, 1998). The surface of the osteoclast forms a ruffled border containing 
extensive folds facing the bone surface. Formation of a tight junction and a ruffled 
border is an indication of osteoclast activation (Teitelbaum, 2000). That region forms 
a subosteoclastic compartment (Howship’s lacuna), in which pH falls, due to the 
action of a proton pump (Everts et al., 1992). Hydrogen ions, produced by carbonic 
anhydrase within the osteoclast, cause acid dissolution of the hydroxyapatite crystals 
in the subosteoclastic compartment (Blair, 1989; Teitelbaum, 2000). The organic 
matrix is subsequently subjected to proteolysis via the action of cathepsin K or 
collagenases or both (Drake et al., 1996; Holliday et al., 1997; Konttinen et al., 2001). 
This process results in the formation of resorption pits (Everts et al., 2002). 
Osteoblasts and osteoclasts are responsible for many physiological processes such as 
bone development and remodeling. All bones develop via endochondral (such as 
mandible) and intramembranous (such as maxilla) bone formation (Gartner and Hiatt, 
1997). Collagen fibers in immature woven bone are not organized into lamellae. In 
mature bone, collagen fibers are re-organized into highly structured lamellae. 
Mechanical loading affects bone remodeling and bone quality according to the law of 
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Wolff (Wolff, 1985). The bone formed can be compact cortical bone or the less dense 
and metabolically more active trabecular bone. The skull skeleton is important for the 
protection of the brain, support of the teeth, and implants, and provision of a frame for 
facial expression. 
8.3 Proteolytic enzymes
8.3.1 Proteinases and their characteristics 
Almost all components of the extracellular matrix can be degraded by matrix 
metalloproteinases (MMPs). The three other major enzyme categories are cysteine, 
serine, and aspartic proteinases. This classification into four main categories is based 
on their mechanism of action, which is dependent on the structure of the catalytically 
active site of the enzyme. The major pathways responsible for the degradation of 
ECM are MMP-, plasmin-, polymorphonuclear leukocyte-, and serine proteinase-
dependent pathways (Birkedal-Hansen et al., 1995). These are pH-dependent, as 
indicated in Table 6. These are cooperatively or independently involved in almost all 
physiological and pathological proteolytic processes such as bone and periodontal 
ligament tissue remodeling, periodontal diseases, oral cancer, loosening of hip 
implants, and rheumatoid arthritis (Cox et al., 1992; Birkedal-Hansen et al., 1995; 
Konttinen et al., 1998; Konttinen et al., 2002). Phagocytic (entirely inside of cells) 
and osteoclastic (in a sealed microenvironment between osteoclast and bone) 
pathways are important, as well (Birkedal-Hansen et al., 1993). 
8.3.1.1 Matrix metalloproteinases. MMPs form a family of neutral endoproteinases 
with at present over 20 known members (MMP-1 to MMP-28). Their common 
denominator is that they are able to function at a neutral (body) pH, under which 
circumstances they can degrade almost all components of the extracellular matrix 
(Brinckerhoff and Matrisian, 2002). On the basis of their substrate specificity and 
structure, MMPs are grouped into collagenases, gelatinases, stromelysins, matrilysins, 
membrane-type MMPs, and various other diverse MMPs, like MMP-20. MMP-20 
degrades amelogenin (Llano et al., 1997; Ryu et al., 1999). 
8.3.1.2 MMP activation. MMPs are tightly controlled at several levels and most are 
not present in normal tissues at high levels. They are produced and secreted or 
released or both by different kinds of activated resident and immigrant host cells. 
Their cellular sources include epithelia, fibroblasts, macrophages, and 
polymorphonuclear leukocytes, but some of them are also found in osteoclasts and 
osteoblasts in bone (Uitto et al., 1998; Lazarus et al., 1968; Birkedal-Hansen et al.,
1995). MMPs are secreted as latent proMMPs (zymogens), which need to be 
activated. Once activated, MMPs initiate tissue destruction if they are able to 
overcome their endogenous inhibitor shield (Birkedal-Hansen, 1995). Therefore, 
production or secretion or both, activation, and inhibition represent key points in the 
regulation of the MMP-driven tissue remodeling and destruction. 
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The cysteine switch has been suggested as the mechanism responsible for the 
activation of proMMPs. Two cysteine-switch activation cascades have been 
identified: one is proteolytic and one non-proteolytic. In the former, the propeptide 
domain in proMMPs, which covers and blocks the enzymatically active catalytic 
domain, is cleaved. The proteolytic activators comprise plasmin, kallikrein, cathepsin 
G, bacterial proteinases, and tumor-associated trypsin-2 (TAT-2) (Eeckhout and Vaes 
G, 1977; Owen et al., 1995; Okamoto et al., 1997; Sorsa et al., 1997). In the latter, the 
non-proteolytic cysteine switch activation cascade, all activators break the Cys97-Zn++
bond and lead to a conformational change in the MMPs. The nonproteolytic activators 
comprise organo-mercurials, hypochlorous acid, and oxidants (Sorsa et al., 1989; 
Saari et al., 1990; Birkedal-Hansen, 1995). 
Figure 4. Modified schematic 
illustration of activation and 
inhibition of MMPs (Libby and 
Lee, 2000). 
8.3.1.3 MMP inhibition. Activated MMPs can be 
inhibited by their endogenous inhibitors in vivo,
with ?2 macroglobulin playing an important role 
in this respect in serum. Due to its large size, it 
has no access to interstitial body fluids. In 
tissues, the tissue inhibitors of 
metalloproteinases (TIMPs) play a major role 
(Libby and Lee, 2000); four TIMPs (TIMP-1, -2, 
-3, -4) have been identified (Brew et al., 2000) 
(Figure 4). Tetracyclines also inhibit collagenase 
(Golub et al., 1985; Suomalainen et al., 1992). 
Chemically modified tetracyclines (CMTs) were 
developed from tetracyclines in the 1980´s 
(Golub et al., 1983). They are non-antimicrobial, 
but they inhibit MMPs, and are promising as 
medication for the modulation of collagen 
degradation in various tissue-destructive diseases 
(Golub et al., 1987; Golub et al., 1998; 
Ramamurthy et al., 2002). 
8.3.2 Collagen degradation
Collagen degradation has been a vital research topic in many diseases such as 
rheumatoid arthritis, loosening of hip implants, periodontitis, and oral cancer 
(Birkedal-Hansen, 1995). The two collagen degradation routes discovered are the 
intracellular and extracellular routes (van der Zee et al., 1997). Type I and III 
collagens are the most common collagens in periodontal and peri-implant tissue 
(Table 5). 
8.3.2.1 Intracellular route. Some of the newly synthesized collagens are degraded 
within the cell before secretion (Bienkowski et al., 1978). It has been calculated that 
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more than 40% of them are degraded at a higher level of adenosine monophosphate 
(Baum et al., 1978), and then the content of collagens in tissues changes. 
Resident cells such as fibroblasts first phagocytose the mature collagen fibrils 
surrounding them. This mature collagen fibril degradation then results in lysosomes 
mediated by acidic cysteine proteinases. This has been nicely demonstrated by 
electron microscopy (Garant, 1976; van der Zee et al., 1997). The intracellular mature 
collagen degradation route is the main pathway in a physiological steady state (Everts 
et al., 1996). 
8.3.2.2 Extracellular route. This route has been suggested to play a major role in 
pathological conditions involving various MMPs (Everts et al., 1996) (Table 6). In 
addition, cathepsin K and TAT-2 may play a role in this route (Koivunen et al., 1991; 
Konttinen et al., 2002; Moilanen et al., 2003). 
8.3.1.2.1 The intra-helical cleavage site. Collagen degradation sites are divided into 
intra- and extra-helical. The intra-helical cleavage site, cleaved by fibroblast-type 
collagenase, was first described in 1962 (Gross and Lapiere, 1962). Fibroblast 
collagenase, later called MMP-1 or collagenase-1, can initially cleave at a single site 
between Gly775-Leu/Ile776 of the triple helix of type I, II, and III collagen fibers (Sakai 
and Gross, 1967). Cleavage at this site results in the generation of a three-quarter 
(TCA) and a one-quarter-length (TCB) collagen degradation fragment (Gross and 
Nagai, 1965; Gross et al., 1974). Both of theses collagen fragments spontaneously 
undergo helix-to-coil transition and are thus denatured into non-helical gelatin 
derivatives at physiological body temperatures (Welgus et al., 1981). Gelatin is 
further rapidly degraded by MMP-1 or by gelatinases such as MMP-2 and MMP-9 or 
by both. Therefore, MMP-1 (and other similar collagenases) act as the rate-limiting 
enzyme in collagen proteolysis (Lehninger et al., 2000). 
In the past several decades, new interstitial collagenases have been identified. 
Collagenase-2 (MMP-8 or neutrophil collagenase) was discovered in 
polymorphonuclear neutrophilic leukocytes (Lazarus et al., 1968). It effectively 
degrades type I collagen (Hasty et al., 1987), and its levels in gingival crevicular fluid 
correlate with periodontal tissue destruction (Lee et al., 1995). Collagenase-3 (MMP-
13) was first discovered in breast cancer (Freije et al., 1994), and later in cartilage and 
synovial membrane, where it effectively degrades type II collagen (Mitchell et al., 
1996; Konttinen et al., 1999). MMP-1 efficiently cleaves type III collagen. MMP-1, 
MMP-8, and MMP-13 constitute the collagenase sub-group (Krane et al., 1996). 
Membrane type-1 MMP (MT1-MMP) has of course collagenase characteristics. MT1-
MMP cleaves the Gly775-Leu776 of ?1(I), which is the classical collagenase cleavage 
site. However, MT1-MMP cleaves the Gly781-Ile782 bond of ?2(I), whereas classical 
collagenases cleave the Gly775-Leu776 bond of ?2(I) (Ohuchi et al., 1997). MMP-2 
(gelatinase-1) is also a collagenase (Aimes and Quigley, 1995; Konttinen et al., 1998); 
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it cleaves triple-helical collagen peptides (Lauer-Fields et al., 2000). Purified human 
neutrophil elastase can cleave native type I collagen and is, in that sense, a 
collagenase. But the exact neutrophil elastase cleavage sites were not identified 
(Kafienah et al., 1998). 
The collagenase-cleaved 1/4 fragment diffuses more quickly out of the cartilage than 
does the larger 3/4 fragment (Vankemmelbeke et al., 1998). The collagen 3/4 
fragment has some interesting feedback functions in vivo. The collagen type I 3/4 
fragment raises the number of focal adhesions of smooth muscle cells (Carragher et 
al., 1999). Collagen degradation fragments are chemotactic to periodontal ligament 
fibroblasts, which initiate the periodontal tissue repair cycle (Terranova and 
Nishimura, 1996). 
8.3.1.2.2 The extra-helical cleavage site. Stromelysin-1 (MMP-3) cleaves collagen at 
a non-helical site (Wu et al., 1991; Clavel et al., 1992). This kind of cleavage leads to 
the removal of cross-links and to depolymerization of the collagen fibrils, i.e., to 
collagen solubilization. MMP-3 is a telo-peptidase (Nakano et al., 1987). 
8.3.1.2.3 Intra- and extra-helical cleavage sites. Cathepsin K has both collagenase and 
telo-peptidase characteristics, and can cleave collagen at multiple intra- and extra-
helical sites (Garnero et al., 1998; Kafienah et al., 1998). It is produced by 
chondrocytes (Konttinen et al., 2002), fibroblasts (Hou et al., 2001), foreign body 
giant cells (Konttinen et al., 2001), odontoclasts (Domon et al., 1999), and osteoclasts 
(Bromme et al, 1996). The intra-helical cleavage sites for cathepsin K are Met159-
Gly160, Ser162-Gly163 and Arg165-Gly166 of the ?1 chain of type I collagen (Nosaka et
al., 1999). 
Bacterial collagenases, produced by pathogenic bacteria in dental or implant plaque, 
cleave at multiple intra- and extra-helical sites (Harrington, 1996). However, it seems 
that the degradation of type I collagen in periodontitis is mainly mediated by 
mammalian collagenases, not by bacterial enzymes (Sorsa et al., 1999; Romanelli et
al., 1999; Soell et al., 2002). 
8.3.3 Features of collagen degradation
8.3.3.1 Collagen degradation in gingival tissue. Two pathological processes have been 
hypothesized to affect tissue destruction in chronic periodontitis. The burst tissue 
destruction concept was first suggested by Socransky et al. (Socransky et al., 1984; 
Soell et al., 2002). This theory states that chronic periodontitis is not a continuously 
active disease progressing at a predictable speed, but is characterized by recurrent and 
random acute episodes. ProMMPs, especially proMMP-1 or proMMP-2, accumulate 
in the extracellular matrix in periodontal tissue. When these proMMPs are suddenly 
activated by activators produced as a result of the action of cytokines such as 
interleukin-1? and epidermal growth factor, a burst of tissue damage ensues (van der 
Zee et al., 1994; van der Zee et al., 1996). Another study testing this hypothesis 
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Table 6: Proteolytic enzymes and some of their characteristic 
General characteristics Type I, II and III collagens cleavage characteristics  
Group Members Cellular sources 
Optimal 
pH 
Collagen cleavage site
Intra-helical                              Extra-helical 
Pathway
IC     EC 
MMPs Collagenases (MMP-1, 8, 13) 
Gelatinases (MMP-2, 9) 
Membrane type MMPs (MT-1, 
2, 3, 4-MMP) 
Stromelysin (MMP-3, 10, 11) 
Others (MMP-19, 20) 
Fibroblasts 
Keratinocytes 
Monocytes 
Macrophages 
Neutrophils 
Osteoclasts 
6?9 Collagenases (I, II, III)1        MMP-3 (I, III)4
MMP-2 (I)2
MT1-MMP (I, II, III)3
             + 
Serine PMN elastase 
Cathepsin G 
Plasminogen activators 
Plasmin 
Plasma kallikrein 
Mast cell chymases 
Tryptase 
Tumor-associated trypsins 
Neutrophils 6?10 PMN elastase (I)5            PMN elastase (III)6
Cathepsin G (II)7
              + 
Aspartic Cathepsin D Breast tumor cells 3.5?5  +  
Cysteine Cathepsin B, H, L, N, K, S, W Osteoclasts 
Foreign body giant cells 
Fibroblasts 
Chondrocytes 
3?7 Cathepsin K (I, II)8       Cathepsin K (I, II)8, 9 +         + 
IC = intracellular pathway, EC = Extracellular pathway; I, II, and III refer to the type of collagen cleaved. 1Gross and Lapiere, 1962; 2Aimes 
and Quigley, 1995; 3Ohuchi et al., 1997; 4Wu et al., 1991; Clavel et al., 1992; 5Kafienah et al., 1998; 6Mainardi et al., 1980; 7Starkey, 1977; 
8Garnero et al., 1998; 9Konttinen et al., 2001.
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suggests that, in chronic periodontitis, MMP-2 may be the main proteolytic enzyme 
responsible for degradation (Kerkvliet et al., 1999). This is compatible with the 
finding that MMP-2 is also a collagenase (Aimes and Quigley, 1995; Konttinen et al., 
1998). 
The other main hypothesis is based on continuous tissue destruction (Reynolds, 1996). 
Its main premise is that the collagen degradation is a result of an imbalance between 
MMPs and their TIMP inhibitor levels. Total MMP activity levels, especially those of 
the collagenases, are supposed to exceed levels of the TIMPs (Sorsa et al., 1992; 
Golub et al., 1997; Romanelli et al., 1999). Some evidence has been published which 
suggests that high net MMP activity leads to continuous tissue destruction (Ingman et
al., 1996; Romanelli et al., 1999). 
8.3.3.2 Bone collagen degradation. Both the cysteine proteinase cathepsin K and 
collagenases are able to hydrolyze type I collagen (Drake et al., 1996; Holliday et al., 
1997). However, it is unknown whether they both participate in osteoclastic bone 
resorption. A recent paper suggests that calvarial osteoclasts are for their activity 
dependent on both cysteine proteinases and MMPs, but long bone osteoclasts are 
mainly dependent on cysteine proteinases. It seems, therefore, that bone resorption by 
cathepsin K or collagenases or both is dependent on type of bone (Everts et al., 1999). 
MMP-9 has been implicated in the degradation of cathepsin- and collagenase-cleaved 
and denatured collagen fragments, and it cleans the bottoms of the bone resorption 
lacunae (Everts et al., 2002). 
Both MMP-1 and MMP-9 are expressed by osteoclasts (Holliday et al., 1997; 
Wucherpfennig et al., 1994). It has been disputed whether it is MMP-1 or MMP-9 
which initiates osteoclast-mediated bone resorption. It seems that MMP-1 from 
osteoblasts is required to initiate bone resorption (Holliday et al., 1997). MMP-9 
seems to be involved in the recruitment of osteoclasts to resorption sites (Blavier and 
Delaisse, 1995). More recently, MMP-9 has been suggested to be involved in bone 
remodeling (Delaisse et al., 2000). 
8.4 Fibronectin and neutrophil elastase
The extracellular matrix is a complex and dynamic meshwork of proteins. In addition 
to collagens, glycoproteins provide structural support to cells, but they also have a 
profound influence on many cellular activities. Increased degradation and/or 
production of fibronectin is involved in many physiological and pathological disease 
conditions, such as chronic leg ulcers (Herrick et al., 1997). 
In chronic periodontitis, the periodontal pathogen Actinobacillus 
actinomycetemcomitans adheres to fibronectin (Mintz and Fives-Taylor, 1999). 
Changes in content of cellular fibronectin are usually caused by its proteolytic 
degradation rather than by changes in its synthesis. Human neutrophil elastase 
effectively degrades cellular fibronectin. Neutrophil elastase has been found to be the 
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most important enzyme able to degrade fibronectin to Fn fragments in vivo
(McDonald et al., 1982). The three elastase cleavage sites are located in the 
transglutaminase, gelatin binding, and cell adhesive fibronectin domains (McDonald 
and Kelley, 1980). Fibronectin has been detected in periodontitis-affected gingival 
tissue (Haapasalmi et al., 1995). Fibronectin degradation fragments are increased in 
gingival crevicular fluid, and their concentration decreases after periodontal treatment 
(Talonpoika et al., 1993). The increased concentration of fibronectin fragments in 
gingival crevicular fluid has been thought to indicate ongoing inflammation and tissue 
destruction (Talonpoika et al., 1989). 
Cellular fibronectin binds to the implant surface (Bagambisa et al., 1994). Titanium 
(Ti) elevates cellular fibronectin in fibroblast culture (Chou et al., 1996). The 
expression of cellular fibronectin is higher in the interface tissue collected from 
revision operations of totally replaced hips (Li et al., 2000). 
8.5 Cytokines in bone resorption
Bone is a dynamically remodeling tissue, in which parts of the old deteriorated bone 
are removed and replaced by new bone, regulated according to the law of Wolff 
(Blair, 1998). This is important for the maintenance of bone quality. The process is 
usually precisely regulated, leading to balanced bone resorption and formation 
(Schwartz et al., 1997). Coupling refers to the fact that under normal conditions bone 
mass is maintained via coupling of osteoclast-mediated bone resorption to osteoblast-
mediated bone formation, which balance each other. This process is regulated by 
hormones and locally by cytokines (Schwartz et al., 1997; Blair, 1998; Raisz, 1999). 
“Cytokine” is a generic term for soluble molecules which mediate interactions 
between cells. Cytokines are relatively small molecules, usually less than 30 kDa in 
size. They are proteins or glycoproteins (Schwartz et al., 1997). They regulate their 
target cells via cell surface-bound cytokine receptors in four different ways: A 
cytokine can have an autocrine, intracrine, juxtacrine, or paracrine mode of action. 
“Autocrine” (Figure 5A) refers to the synthesis of a cytokine by one cell that 
influences the growth and functional activities of the cells producing that cytokine via 
a specific receptor on its surface (Klinger et al., 1998). “Intracrine” (Figure 5B) refers 
to the direct action of a cytokine on a cell. Cytokines are produced as cytokine and 
receptor complexes that are rapidly internalized by the cells and translocated to the 
nucleus without being degraded. The cytokines contain a nuclear transport sequence 
that mediates the transport of this cytokine into the nucleus. “Juxtacrine” refers to 
regulatory actions exerted between cells (from one cell to another cell). There are two 
kinds of contacts between cells communicating in a juxtacrine manner. One contact is 
mediated via a membrane-bound cytokine, which interacts with the cytokine receptor 
on the adjacent cell (Figure 5C). The other mode of juxtacrine action is mediated via a 
pericellular matrix-associated cytokine, which interacts with receptors on a 
neighboring cell (Figure 5C). “Paracrine” refers to the fact that cytokines expressed 
by one type of cell are secreted into body fluids and influence the activities of some 
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other remote cells, which express receptors for this cytokine in that tissue (Figure 5D) 
(Klinger et al., 1998). Juxtacrine and paracrine modes of action are important in 
osteoclast formation. Hormones, which are not classified as cytokines, are secreted by 
endocrine glands and reach their target cells via the circulation. Some cytokine effects 
can be classified as endocrine, such as the hepatocyte-mediated acute-phase response 
stimulated by IL-6 produced locally in inflamed tissue. 
Figure 5: Cytokines and their working manner on osteoclasts (Klinger et al., 1998) 
A = autocrine, B = intracrine, C = juxtacrine, D = paracrine. 
Osteoclasts develop from progenitor cells (monocytes) circulating in the blood. They 
migrate to bone as monocytes where they differentiate into tissue macrophages, which 
constitute the local precursor cells for osteoclasts. Monocyte/macrophages have some 
cytokine and growth factor receptors, such as receptors for macrophage colony-
stimulating factor and receptor for activator of nuclear factor kappa B ligand (earlier 
also known as osteoclast differentiation factor) (Perkins and King, 1995). These 
growth factors and cytokines can stimulate pre-osteoclast progenitor cells to fuse and 
to differentiate into multinucleated osteoclasts (Pfeilschifter et al., 1989; Schwartz et
al., 1997). TNF-? and IL-1? may also independently stimulate osteoclastogenesis 
(Kaji et al., 2001). In osteoclast differentiation, receptor tyrosine kinases and the 
Janus kinase-signal transducer and activator of transcription pathways are the two 
main signal transducer systems (Katagiri et al., 2001; Hayashi et al., 2002). Currently, 
research aiming to regulate osteoclast activity is focused on receptor activation of 
nuclear factor kappa B ligand and its decoy receptor osteoprotegerin. If the receptor 
activator of nuclear factor kappa B ligand binds to its decoy osteoprotegerin instead of 
to its cellular receptor, its action is neutralized (Horowitz et al., 2001; Kanzaki et al., 
2001). 
Some of the cytokines can be grouped into osteoclast- or osteoblast-stimulating 
cytokines, depending on their regulatory effects on osteoclast or osteoblast (Konttinen 
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et al., 1997). Many osteoclast-stimulating cytokines have been found, although many 
of them may have an indirect mode of action via the receptor activation of the nuclear 
factor kappa B system in Table 7 (Wright and Goodman, 2000). Many of them are 
produced by multiple resident or immigrant cells in peri-implant tissues. Producer 
cells include fibroblasts, keratinocytes, monocyte/macrophages, foreign body giant 
cells, osteoclasts and osteoblasts (Koka and Reinhardt 1997; Giudiceandrea et al., 
1998; Sandros et al., 2000; Xu et al., 2000). Increased osteoclast numbers and 
osteoclast activity contribute to pathological bone loss in periodontitis, to loosening of 
hip implants, and to osteoporosis (Schwartz et al., 1997; Konttinen et al., 1997; 
Tervahartiala et al., 2001). Peri-implant bone loss has not, however, been studied in 
this respect to assess whether osteoclast-stimulating cytokines are increased around 
loosening dental implants. 
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Table 7: Some bone metabolism-regulating cytokines.
Cytokine Target cell in bone Effects on bone 
Interleukin-1 Osteoblast, osteoclast Formation +/?;
Resorption+/?
Interleukin-3 Osteoclast Resorption + 
Interleukin-6 Osteoblast, osteoclast Formation ?; Resorption + 
Interleukin-8 Osteoblast, osteoclast Resorption + 
Interleukin-11 Osteoclast Formation ?; Resorption + 
Tumor necrosis factor-? Osteoblast, osteoclast Resorption + 
Tumor necrosis factor-? Osteoblast, osteoclast Resorption + 
Macrophage colony-stimulating 
factor 
Osteoclast Resorption + 
Granulocyte-macrophage 
colony-stimulating factor 
Osteoblast, osteoclast Resorption + 
Epidermal growth factor Osteoblast, osteoclast Formation +; Resorption + 
Transforming growth factor-? Osteoblast, osteoclast Formation ?; Resorption + 
Transforming growth factor-? Osteoblast, osteoclast Formation +; Resorption +/?
Platelet-derived growth factor Osteoblast, osteoclast Formation +; Resorption + 
Acidic fibroblast growth factor Osteoblast Formation + 
Basic fibroblast growth factor Osteoblast Formation + 
Insulin-like growth factor Osteoblast, osteoclast Formation +; Resorption + 
Interferon-? Osteoblast, osteoclast Resorption ?
Osteoprotegerin Osteoblast, osteoclast Resorption ?
Receptor activator of nuclear 
factor B ligand 
Osteoclast Resorption + 
Bone morphogenetic protein-2 Osteoclast Formation+; Resorption ?
+, Stimulation; +/?, Stimulation or inhibition; ?, Inhibition.  
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6. AIMS OF THE STUDY 
1. To assess whether collagenase (MMP-8, MMP-13) levels in peri-implant 
sulcus fluid correlate with peri-implant bone loss. 
2. To investigate activated and total gelatinase-B activity levels in peri-implant 
sulcus fluid and their eventual correlation with the Gingival Index and peri-
implant bone loss. 
3. To assess cellular fibronectin in peri-implantitis in comparison to chronic 
periodontitis and healthy gingival control tissue. 
4. To assess the eventual presence of the collagenase-produced type I collagen 
fragment neoepitope in chronic periodontitis-affected gingival tissue compared 
to healthy gingival control tissue. 
5. To assess in peri-implantitis the eventual presence of cytokines which mainly 
activate osteoclasts, namely IL-1?, IL-6, TNF-?, PDGF-A, and TGF-?.
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7. MATERIALS AND METHODS
7.1 Patients and samples
1) Peri-implant sulcus fluid (PISF) samples. PISF samples were collected with filter 
strips (Brill 1962; Ingman et al., 1994). One strip was placed gently in the opening of 
the peri-implant margin approximately 1 mm into the sulcus for 4 minutes. The fluid 
absorbed by the strip was eluted in 50?L 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 
1mM CaCl2. The eluate was centrifuged, and aliquots of the supernatant were stored 
at -20°C. 
2) Gingival tissue samples. Peri-implant gingival tissue specimens were obtained at 
the time of removal (revision) of dental implants performed due to clinical failure at 
the Department of Oral and Maxillofacial Surgery, Institute of Dentistry, Helsinki, 
Finland. All the patients had radiological and clinical evidence of loosening, namely 
pain when masticating, increased mobility of the implant, and peri-implant vertical 
bone loss in X-ray. For comparison, chronic periodontitis samples were received from 
patients who required periodontal flap surgery treatment. All gingival tissue samples 
were immediately snap-frozen in liquid nitrogen, embedded, and frozen in OCT 
(Optimal Compound for Tissue embedding) compound (Lab-Tek Products, Miles, 
Laboratories, Elkhart, IN, USA). Samples were stored at -80°C. 
3) Ethical aspects. Patient participation in this study did not endanger their health. 
They underwent procedures deemed necessary for their oral health. Participation did 
not involve them in any extra dental procedures. Samples were used for scientific 
research on loosening of dental implants. Participation was voluntary. All patients 
gave their informed consent. The Declaration of Helsinki (Hong Kong amendment, 
September 1989) was followed in our work. The project was approved by the local 
ethics committee of the participating institutes. 
4). Antibodies: The primary antibodies used in the study are listed in Table 8. 
7.2 Immunofluorometric assay
An immunofluorometric assay was used to measure collagenase-2 (MMP-8) levels in 
PISF. Monoclonal mouse anti-human MMP-8 antibodies 8708 (Medix Biochemica, 
Kauniainen, Finland) and polyclonal rabbit anti-human 8706 (Medix Biochemica) 
were used, Monoclonal 8708 antibodies were used to coat 96-well plates. Samples in 
assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 50 ?M ZnCl2,
0.5% bovine serum albumin) were incubated in the coated wells for 1 hour, after 
which the wells were washed. Polyclonal antibody 8706 was labeled with an 
europium chelate and used as the tracer (Hemmilä et al., 1984), and 100 ?L of assay 
buffer containing the tracer antibody was added. After 1 hour incubation, the wells 
were washed, and 100 ?L of enhancement solution (Wallac, Turku, Finland) was 
added to each well. The fluorescence was measured after 5 minutes with a 1234 
Delfia Research Fluorometer (Wallac, Turku, Finland). Collagenase-2 levels are 
expressed as ng/mL (Hanemaaijer et al., 1997). 
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Table 8: Primary antibodies of this study and some of their characteristics
Antibody Antigen Source Reference Articles 
Collagenase-2 MoAb 8708 Mouse Hanemaaijer et al., 1997 I 
Collagenase-2 MoAb 8706 Rabbit Hanemaaijer et al., 1997 I 
Collagenase-3 181-15A12 Rabbit Freije et al., 1994 I 
Gelatinase-B TNO-S22.2 Mouse Hanemaaijer et al., 1998 II 
Cellular fibronectin 
(EDA-cFN) 
52DH1 Mouse Vartio et al., 1987 III 
Integrin ?4 subunit A4-PUJI  Mouse Pujades et al., 1996 III 
Integrin ?5 subunit SAM-1 Mouse Pujades et al., 1996 III 
Integrin ?1 subunit 102DF5 Mouse Ylänne et al., 1989 III 
 COL2-3/4Cshort COL1-3/4 
neoepitope 
Rabbit Billinghurst et al., 1995 
Sukhova et al., 1999 
IV 
TNF-? E.coli-derived rh 
TNF-?
Goat Vector Laboratory, 
Burlingame, CA, USA 
V
IL-1? ILA8-H12 Mouse Endogen, Woburn, MA, USA V 
IL-6 Yeast-derived rh 
IL-6 
Rabbit Vector Laboratory V 
PDGF-A human rh PDGF-
AA 
Rabbit Genzyme, Cambridge, MA, 
USA 
V
TGF-? clone 213-4.4 Mouse Oncogene Research Products, 
Cambridge, MA, USA 
V
7.3 Modified pro-urokinase gelatinase-B activity assay
The 96-well plates (Costa, Mesa, CA, USA) were coated with 100 ?L (5 ?g/mL) 
gelatinase-B specific monoclonal TNO-S22.2 antibodies developed by Hanemaaijer 
and coworkers (Hanemaaijer et al., 1998) for 16 hours at +22?C and washed three 
times with PBS (10mM sodium phosphate, 0.15M NaCl, pH 7.5) containing 0.05% 
Tween-20. Purified gelatinase-B as a positive control or 5 ?l PISF samples were 
added and incubated for 16 hours at +4?C. The wells were washed three times with 
PBS with 0.05% Tween-20 and incubated with assay buffer (50 mM Tris-HCl, 150 
mM NaCl, 5 mM CaCl2, 1 ?M ZnCl2, 0.01% Brij-35, pH 7.6), and 15 ?L 50 ?g/mL 
modified pro-urokinase containing a MMP-specific activation site and 10 ?L 6 mM 
chromogenic urokinase substrate pyro-Glu-Gly-Arg-p-nitroanilide (Chromogenix, 
Mölndal, Sweden) were added. The color was measured in a Titertek Multiskan 8-
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channel photometer (Flow Laboratories, Irvine, Scotland). The results are expressed 
as U/mL (Verheijen et al., 1997; Hanemaaijer et al., 1998). 
To measure total gelatinase-B activity, PISF samples were first incubated with 0.5 
mM 4-aminophenylmercuric acetate (APMA) (Sigma) for 2 hrs at +37?C to activate 
progelatinase-B. The assay detects as little as 3.75 x 10-15 mol gelatinase-B in 
biological fluid samples (Verheijen et al., 1997).
7.4 Quantitative immunoblot technique
The diluted PISF samples adjusted to contain 2 ?g protein were treated with 
Laemmli´s buffer, pH 6.8, containing 5 mM dithiothreitol, and heated for 5 minutes at 
+100?C. High- and low-range prestained SDS-PAGE standards (Bio-Rad, Hercules, 
CA, USA) served as molecular weight markers. Samples were separated on 8 to 10% 
SDS-polyacrylamide cross-linked gel at 200 V for 45 minutes and electrophoretically 
transferred to a nitrocellulose membrane (Bio-Rad). Non-specific binding was 
blocked by incubation with 3% gelatin in 10 mM Tris-HCl, pH 8.0, containing 22 mM 
NaCl and 0.05% Tween. This membrane was incubated with polyclonal rabbit anti-
human MMP-13 IgG overnight at +20?C. The MMP-13 antibody was used at a 
concentration of 0.5 ?g/mL. After repeated washings, the membrane was incubated 
with alkaline phosphatase-labeled anti-rabbit immunoglobulins (Sigma) (1:100) for 1 
hour at +20?C. After a 15-minute washing with 10 mM Tris-HCl, pH 8.2, containing 
22 mM NaCl and 0.05% Tween washing buffer, the color was developed by addition 
of nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate diluted with N-
N-dimethyl-formide (Sigma) in 100 mM Tris-HCl, pH 9.5, containing 5 mM MgCl2
and 100 mM NaCl. The secondary antibody alone did not recognize the band detected 
with specific antibodies in immunoblotting. Known concentrations of MMP-13 were 
used in all tests as positive controls and standards for quantitative immunoblots. 
Immunoblots were quantitated by image densitometer (Model G5-700, Bio-Rad) and 
the Molecular Analyst Program (Image analysis system version 1.4). Results are 
expressed as ng per mL (Golub et al., 1998). 
7.5 Immunohistochemical avidin-biotin-peroxidase complex (ABC) staining
Two 6-?m cryostat cut gingival sections were mounted on gelatin-formalin-coated 
glass slides and fixed in cold acetone at +4?C for 5 minutes. After washes with 20mM 
Tris-HCl, 150 mM NaCl, pH 7.4 (TBS), endogenous peroxidase was inhibited by 
incubation in 0.4% H2O2 in methanol at room temperature for 30 minutes. The 
staining was done by use of the Vectastain® Elite ABC mouse Kit (Vector 
Laboratories, Burlingame, CA, USA). Briefly, serial sections were incubated with 
normal horse serum (diluted 1:50 in TBS containing 0.1% bovine serum albumin) at 
room temperature for 20 minutes. After blotting of the excess serum, the sections 
were treated at room temperature with: 1) primary antibodies diluted in TBS 
containing 0.1% BSA overnight at +4?C. 2) biotinylated IgG (dilution 1:100, Vector) 
at +22?C for 30 minutes, and 3) avidin-biotin-peroxidase complex (1:100 in TBS; 
Vector Labs). The sites of peroxidase binding were revealed by incubation in 3,3'-
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diaminobenzidine tetrahydrochloride (Sigma) in 0.006% H2O2 at +22?C for 1 to 10 
minutes in darkness. 
Normal IgG of the same subtype but with irrelevant specificity was used instead of 
and at the same concentration as the primary antibodies as a negative staining control 
to confirm the specificity of the immunohistochemical staining results. One synovial 
membrane sample from a rheumatoid arthritis patient was severed as a positive 
sample control in each staining. Both the negative staining and positive sample 
controls confirmed the specificity of immunohistochemical staining results.  
One of the sections on each slide was counterstained with Harris hematoxylin for one 
minute. The sections were dehydrated in a graded ethanol series, cleared in xylene, 
and mounted in synthetic mounting medium (Diatex, Becker Industrifärg AB, Märsta, 
Sweden). 
7.6 Microscopic morphometric evaluation
Microscopic morphometric evaluation (quantitative assessment) was performed with a 
low-light charge-screen coupled with a 12-bit PC digital image camera (SensiCam, 
Kelheim, Germany) mounted on a Leitz Diaplan (Ernst Leitz, Wetzlar, Germany) 
light microscope linked to a semiautomatic Analysis Pro 3.0 image analysis and 
processing system (Soft Analysis System GmbH, Münster, Germany). Morphometry 
was performed under x 400 magnification on tissue sections without counterstaining. 
The whole section area was analyzed (Xu et al., 2000). After adjustment of 
illumination and focus, the image was recorded in digitalized form in a computer. 
After setting the threshold for the optimal signal-to-noise ratio, it was used for the 
whole sample during the procedure. The results of quantitative assessment are 
expressed as percentage of positively staining area of the total tissue area (Xu et al., 
2000). 
7.7 Statistical methods
Statistical calculations were made using BMDP 2.0 for Windows software (Los 
Angeles, CA, USA). The value for a statistically significant difference was set at 0.05. 
Shapiro and Wilk´s W test were first used to test the data for normality. 
Normally distributed data are expressed as means and standard deviations. Non-
normally distributed data are expressed as means and interquartiles (Q3, Q1, and [Q3-
Q1]). For analysis of the eventual statistical difference between two groups, the un-
paired t-test was used for normally distributed groups, whereas the Mann-Whitney 
rank sum test was used if at least one of the two groups had a non-normal distribution. 
For three group comparisons, the Kruskal-Wallis test was used for normally 
distributed data, whereas one-way analysis of variance (ANOVA) was used for non-
normally distributed data. Correlations between two groups were calculated using 
Spearman’s rank correlation for normally distributed variables and the Pearson rank 
test for non-normally distributed variables. 
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8. RESULTS
8.1 Collagenase levels differed between different peri-implant vertical bone loss 
groups (I)
Collagenase-2 (n = 6, 2021 ± 1038, p<0.05) and collagenase-3 (16 ± 4, p<0.05) in 
peri-implant sulcus fluid were higher (Kruskall-Wallis test) in the group which had 
lost more than 3 mm of bone than in the two other groups with < 1 mm (n = 32, 861 ± 
164 and 10 ± 1, respectively) or 1 to 3 mm (n = 11, 1265 ± 508 and 12 ± 2, 
respectively) of bone loss. A significant linear correlation appeared between site-
specific collagenase-2 and collagenase-3 levels (r = 0.692, p < 0.005) (Pearson rank 
test). 
8.2 Gingival indices did not differ between different peri-implant vertical bone 
loss groups (I) 
Gingival index results showed no differences among different peri-implant vertical 
bone loss groups (0.6 ± 0.1 in patients with < 1 mm bone loss, 0.6 ± 0.5 in patients 
with 1-3 mm bone loss, and 1.2 ± 0.3 in patients with more than 3 mm bone loss, p >
0.05, Kruskall-Wallis test). 
8.3 Gelatinase-B levels in PISF correlated with peri-implant vertical bone loss 
(II)
Degree of in vivo activated gelatinase-B correlated (r = 0.942, p < 0.0001) with total 
gelatinase-B (n = 46, Spearman's rank correlation test). Both total gelatinase-B (r = 
0.553, p = 0.021) and activated gelatinase-B levels (r = 0.529, p = 0.003) in PISF 
correlated with peri-implant bone loss (n = 46, Spearman's rank correlation test). Total 
gelatinase-B (median = 1375, Q3 =2079, Q1 = 445, [Q3 ? Q1] = 1633) and activated 
gelatinase-B (median = 458, Q3 = 979, Q1 = 200, [Q3 ?Q1] = 979) levels were 
increased in the group with > 3 mm peri-implant bone loss compared to < 1 mm (total 
gelatinase-B, median = 183, Q3 = 558, Q1 = 78, [Q3-Q1] = 480, p = 0.013; activated 
gelatinase-B, median = 133, Q3 = 275, Q1 = 50, [Q3?Q1] = 225, p = 0.015) and 1 to 
3 mm groups (total gelatinase-B, median = 250, Q3 = 583, Q1 = 50, [Q3?Q1] = 533, 
p = 0.027); (activated gelatinase-B, median = 166, Q3 = 233, Q1 = 33, [Q3?Q1] = 
200, p = 0.035) group (Rank sum test). 
8.4 Gelatinase-B levels in PISF differed between gingival index groups (II)
Activated gelatinase-B level (median = 225, Q3 = 375, Q1 = 108, [Q3-Q1 = 267]) in 
the GI > 0.5 group was higher than that in the GI = 0 (median = 50, Q3 = 142, Q1 = 
17, [Q3 ?Q1 = 125], p = 0.012) and GI ? 0.5 (median = 216, Q3 = 425, Q1 = 50, [Q3 
?Q1 = 375], p = 0.17) group (Rank sum test). Total gelatinase-B levels in the GI > 0.5 
(median = 350, Q3 = 258, Q1 = 42, [Q3?Q1 = 216]) and GI ? 0.5 (median = 417, Q3 
= 1083, Q1 = 171, [Q3-Q1 = 912], p = 0.02) groups were clearly high compared to the 
GI = 0 (median = 83, Q3 = 258, Q1 = 42, [Q3-Q1 = 217], p = 0,043) group (Rank sum 
test).  
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8.5 Cellular fibronectin staining was higher in gingival tissue (III)
All gingival samples showed immunoreactivity to cellular fibronectin. The staining 
pattern of cellular fibronectin was similar in peri-implantitis, chronic periodontitis, 
and in normal healthy controls. The staining intensity of cellular fibronectin in the 
extracellular matrix varied among different regions of the peri-implant and gingival 
tissue samples. Cellular fibronectin staining was stronger in the blood vessel wall than 
in the surrounding perivascular and interstitial matrix. Intense cellular fibronectin 
staining was also evident in the epithelial basement membrane and in the lamina 
propria, especially in connective tissue papillae. Oral epithelium did not stain for 
cellular fibronectin. The staining of other areas in the lamina propria dominated by 
fibroblasts was less conspicuous. Foreign bodies, probably of implant- or surgical 
instrument-derived metal, were embedded in the extracellular matrix as small, round 
particles. Most such particles were surrounded by a cellular fibronectin layer 
approximately 5 to 10 ?m thick. Staining controls with monoclonal mouse IgG1 with 
an irrelevant specificity were negative. 
Cellular fibronectin was high in peri-implantitis compared to that in healthy gingival 
control tissue (n = 10, 33 ± 5% vs 12 ± 1%, p = 0.003). In contrast, cellular 
fibronectin staining was low in chronic periodontitis compared to that in healthy 
gingival control tissue (6 ± 1% vs 12 ± 1%; p = 0.006). 
8.6 Distribution of integrin receptors for cellular fibronectin in gingival tissue 
(III)
?4 subunit. Keratinocytes were integrin ?4 subunit-negative. Some integrin ?4
subunit positive fibroblasts were visible in the connective tissue stroma. Almost all 
endothelial cells in postcapillary venules and capillaries were negative or at most 
weakly positive for the integrin ?4 subunit. 
?5 subunit. The integrin ?5 subunit was strongly expressed in the endothelium of 
postcapillary venules and capillary blood vessels, in particular in the connective tissue 
papillae. Fibroblasts were only weakly positive. No integrin ?5 subunit-positive cells 
were found in the oral epithelium. 
?1 subunit. The integrin ?1 subunit was strongly expressed in the basal cell layer of 
the oral epithelium and in some cells of the stratum spinosum, but in no other layers 
of the oral epithelium. Immunoreactivity almost as strong occurred in vascular 
endothelial cells, and comparatively weak staining in fibroblasts in the lamina propria. 
The distributions of integrin subunits binding cellular fibronectin were studied, but no 
significant differences were found between periodontitis and loosening dental 
implants. 
8.7 Increased staining of collagenase-cleaved collagen fragments (cCOL1-3/4C) 
in un-treated chronic periodontitis (IV)
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Moderate cCOL1-3/4C staining appeared in the submucosa below the sulcular and 
junctional epithelium in chronic periodontitis-affected gingival tissue samples. Similar 
staining of moderate intensity was observable around some of the fibroblasts 
embedded in the periodontal connective tissue matrix. In addition, most of the 
interstitial collagen in areas infiltrated by inflammatory mononuclear cells stained 
with the COL1-3/4C antibodies. Control samples contained some COL1-3/4C 
immunoreactivity (1.6 ± 0.7%; n = 10) below the sulcular and junctional epithelium, 
but the extent of this staining was less than that in chronic periodontitis (6.3 ± 1.2%; n 
= 10; p ? 0.005, unpaired student t test). Some pilot studies on collagenase-cleaved 
collagen neoepitopes were also done on peri-implant tissues still available at that time 
of the thesis work, but the sample sizes were small and the results were inconsistent. 
Therefore, these results were not published. 
8.8 Increased expression of osteoclast-stimulating cytokines in gingival tissue in 
chronic periodontitis and implantitis (V)
Perivascular mononuclear cell infiltrates in the lamina propria in chronic periodontitis 
contained mainly macrophages. In peri-implantitis, multinuclear foreign body giant 
cells were frequently observable. Many of the macrophages in chronic periodontitis 
and peri-implantitis contained immunoreactive cytokines. All of the foreign body 
giant cells always contained all of the osteoclast-stimulating cytokines analyzed in the 
present study. Some of the fibroblast-like cells contained IL-1? and TNF-?, but IL-6, 
PDGF-A, and TGF-? also appeared in such cells. Normal healthy gingival control 
tissue contained only a few cytokine immunoreactive cells. 
TNF-?, IL-1?, IL-6, PDGF-A, and TGF-? positive cells appeared in the basal cell 
layer of sulcular epithelium, with a few cytokine immunoreactive cells visible in the 
prickle-cell layer. Staining intensity was most conspicuous in chronic periodontitis, 
followed by peri-implantitis and normal healthy controls in this ranking order. TNF-?,
IL-1?, and IL-6 immunoreactive cells were most numerous in chronic periodontitis 
and peri-implantitis. PDGF-A and TGF-? immunoreactive cells were no more 
frequent in chronic periodontitis than in healthy gingival control tissues. 
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9. DISCUSSION
Dental implant materials dramatically developed during the past half century after 
introduction of osseointegration, a remarkable milestone in dentistry (Brånemark et 
al., 1977). Dental implants meet multiple demands with regard to function and 
aesthetics, and mechanical failures have decreased as a result of development of 
implant materials (Adell et al., 1985; Kronström et al., 2002). Osseointegration can be 
achieved more often than before due to improvement in surgical methods and 
equipment, but loosening of dental implants has become a major problem in implant 
dentistry (Duyck and Naert, 1998; Esposito et al., 1998a, b; el Askary et al., 1999). 
Many risk factors increase the rate of loosening (Esposito et al., 1998a; el Askary et
al., 1999): Nonbiocompatible implant materials constitute one important risk factor, 
because they cause adverse host responses (Edgerton and Levine, 1993; Santavirta et
al., 1999). All risk factors affect pathomechanisms responsible for loosening (Figure 
3). One of the main features of the process is progressive loss of peri-implant support 
tissues (Tonetti and Schmid, 1994; Duyck and Naert, 1998). Many proteolytic 
enzymes are increased around loosening dental implants (Ingman et al., 1994; 
Teronen et al., 1997; Sorsa et al., 1999) and in chronic periodontitis (Reynolds and 
Meikle, 1997; Romanelli et al., 1999). We followed and extended the previous work 
on proteolytic enzymes and also studied osteoclast-stimulating cytokines, because 
osteoclasts seem to play an important role in peri-implant bone tissue destruction 
during loosening of dental implants. 
9.1 Collagenase-2, -3, and gelatinase-B involved in peri-implant bone loss
Type I collagen is the dominant organic component in bone tissue (Table 5). Its 
proteolytic degradation is an important step in pathological bone tissue destruction 
(Birkedal-Hansen et al., 1993). Cathepsin K cleaves the collagen triple helix at intra- 
and extra-helical sites (Blair, 1998; Garnero et al., 1998). Collagenases (collagenase-
1, 2, 3) cleave triple helical type I collagen fibers at one site only (Gross and Lapiere, 
1962). Both cysteine proteinases and MMPs seem to be involved in bone resorption. 
Cathepsin K and collagenase-3 are expressed by osteoclasts (Bromme et al, 1996; 
Kusano et al., 1998). Both cathepsin K and MMPs such as proMMP-1 are detectable 
in the subosteoclastic compartment (Everts et al., 1992; Delaisse et al., 1993; Everts 
et al., 1998). Recently, cathepsins, not collagenases, have been suggested to be 
responsible for the resorption of long enchondral bones, such as in loosening of hip 
implants (Everts et al. 1999; Konttinen et al. 2001). However, both cathepsins and 
certain collagenases are required for osteoclastic resorption of calvarial/ membranous 
bone (Everts et al., 1999). Unfortunately, no report exists on the eventual presence of 
cathepsin K in peri-implant sulcus fluid or gingival crevicular fluid. In contrast to 
cathepsin K, cathepsin C has been found in chronic periodontitis tissue (Soell et al., 
2002). 
Collagenase-3 is required for the migration of pre-osteoclasts during the development 
of the bone marrow cavity in long bones (Blavier et al., 1995). It contributes to the 
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degradation of unmineralized bone matrix on the bone surface, which is assumed to 
be the first step in bone resorption (Uchida et al., 2001). Increased expression of 
collagenase-3 has been suggested to be typical for foreign body reactions, which 
probably contributes to aseptic loosening of total hip implants (Imai et al., 1998). The 
elevated collagenase-3 activity in gingival crevicular fluid associated with bone loss 
suggests that it may contribute to bone collagen degradation in chronic periodontitis 
(Golub et al., 1997). These observations may explain why, in our patients with 
advanced vertical bone loss, collagenase-3 levels in PISF were high. It remains 
unclear, however, if and how collagenase-3 or any of the neutral MMPs contributes to 
bone loss. 
The role of collagenase-2 in bone resorption is debatable. It was first found in 
polymorphonuclear neutrophilic leukocytes (Lazarus et al., 1968), and later was also 
detected in many other cell types. It has been described in periodontal ligament cells 
(Salo et al., 1995), articular chondrocytes (Cole et al., 1996), synovial fibroblasts and 
endothelial cells (Hanemaaijer et al., 1997), odontoblasts, and dental pulp cells 
(Palosaari et al., 2000). Collagenase-2 is also expressed in chicken and rat osteoclasts, 
but not in human osteoclasts (Sorsa et al., 1998). 
Rats have collagenase-2 and -3, but contrary to earlier belief, they lack collagenase-1 
(MMP-1). Such tetracycline analogs, which inhibit MMPs, have been found to reduce 
bone destruction in a model in which rat osteoclasts digest bovine bone. This implies 
that collagenase-2 or -3 or both are involved in bone resorption (Greenwald et al., 
1998). Collagenase-2 is related to many developmental and metabolic bone diseases, 
and is required for the normal development of mandibles and hind limbs in rats 
(Sasano et al., 2002). Collagenase-2 in GCF has been studied in both adult and 
juvenile periodontitis (Ingman et al., 1993); its activity in GCF is typical for chronic 
periodontitis, and its activity levels correlate with periodontal bone loss (Sorsa et al., 
1988; Lee et al., 1995; Romanelli et al., 1999). Relatively high collagenase-2 levels 
occur in PISF around loosening implants compared to those in well-fixed implants 
(Teronen et al., 1997). These observations have now been extended by our 
demonstration that collagenase-2 levels in PISF correlated with degree of vertical 
bone loss. 
Gelatinases (gelatinase-A and B) form a sub-group of the MMP family. Gelatinase-
B/MMP-9, but not gelatinase-A/MMP-2, is expressed by human osteoclasts 
(Wucherpfennig et al., 1994; Okada et al., 1995). Logically, gelatinase-B has been 
recently found to be involved in bone remodeling (Delaisse et al., 2000). It is involved 
with the recruitment of osteoclasts to resorption sites (Blavier and Delaisse, 1995). 
Gelatinase-B from osteoclasts proteolytically activates transforming growth factor-
beta, which is deposited in the bone matrix and plays a regulatory role in bone 
remodeling (Dallas et al., 2002). 
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Gelatinase-B/MMP-9 degrades cathepsin-produced multiple collagen fragments and 
collagenase-produced 3/4 and 1/4 collagen fragments, which have been spontaneously 
denatured to gelatin (Birkedal-Hansen 1995; Kusano et al. 1998). Gelatinase-B is a 
cooperative enzyme acting in concert with collagenases in collagen degradation. 
Furthermore, gelatinase-B has been found to remove bone collagen remnants left by 
osteoclasts in resorption lacunae. This is an obligatory step in the linkage between 
bone resorption and bone formation (Delaisse et al., 2000; Everts et al., 2002). In 
other words, gelatinase-B is important for the activation-resorption-formation cycle 
(ARF cycle) (Lassus et al., 1998). Quite in line with these observations, it has been 
reported that a specific synthetic gelatinase inhibitor prevents bone resorption (Hill et
al., 1994). 
Gelatinase-B exists in many immigrant and resident cells. In chronic periodontitis, 
polymorphonuclear neutrophilic leukocytes, monocyte/macrophages, and 
keratinocytes produce gelatinase-B (Salo et al., 1991; Westerlund et al., 1996), and is 
also expressed by odontoclasts, which participate in deciduous root resorption 
(Linsuwanont et al., 2002). In this work, gelatinase-B levels were associated with the 
extent of peri-implant bone loss. Future studies should evaluate the true prognostic 
value of the markers identified and the effect of therapeutic interventions targeting 
them. 
9.2 Gingival index and peri-implant bone loss
Gingival index, a useful clinical periodontal index used in the diagnosis of gingivitis 
(Löe, 1967; Ainamo and Bay, 1975), is helpful for evaluation of degree of 
inflammation in gingival tissue in gingivitis and chronic periodontitis (Löe, 1967; 
Ainamo and Bay, 1975). Gingival index has been modified to make it suitable for 
assessment of inflammation around dental implants (Chaves et al., 1993; Mombelli et
al., 1987), and both gingival index and the modified gingival index serve to describe 
and quantitate disease activity (Ciancio et al., 1986). The value of the gingival index 
may be affected by many factors and changes in terms of time and stages of disease. 
Compared to gingival index, peri-implant vertical bone loss is an important measure 
of disease outcome, which is quite stable. This is a pathological result of all kinds of 
implant risk factors and mechanisms. It is generally accepted that peri-implant bone 
loss is related to adverse biological host responses together with cyclic occlusal 
loading and oral bacterial pathogens (Gross, 1988; Swanberg and Henry, 1995; 
Leonhardt et al., 1999; Santavirta 1999). Because gingival index reflects gingival 
inflammation, which is generally caused by bacterial pathogens, a high gingival index 
may not be related to high peri-implant vertical bone loss. Indeed, it was observed in 
this study that gingival index did not correlate with peri-implant boss loss. 
In contrast, in another study, a high gingival index was positively correlated in many 
peri-implantitis affected patients with bone vertical resorption (Mombelli et al., 1987; 
Luterbacher et al., 2000). Gingival index is a useful clinical criterion, but the 
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relationship between gingival index and peri-implant bone loss is not yet clear. 
Mechanical peri-implant bone loss, not necessarily reflected in gingival index, should 
not be neglected (Redlich et al., 2001; Engquist et al., 2002), because abnormal 
mechanical loading may have serious consequences for implant patients. Prevention 
of peri-implant bone loss is thus a key question in dental implantology, because peri-
implant bone is the strongest tissue among all peri-implant support tissues 
(Albrektsson et al., 1986). 
Our current view on mechanical bone loss is that it is induced by multiple bone-
destructive proteinases. High mechanical forces induce osteocytes to produce 
cathepsin K and collagenase-1 (Kurata et al., 2001; Redlich et al., 2001). Both 
cysteine proteinases and MMPs are required for bone resorption (Everts et al., 1992; 
Everts et al., 1998). Especially cathepsin K inhibitors have been intensively 
developed for treatment of diseases associated with bone and cartilage destruction 
(Votta et al., 1997). Chemically modified tetracyclines are now available, which have 
been shown to have anti-MMP features (Golub et al., 1987; Golub et al., 1998; 
Ramamurthy et al., 2002). Such drugs might offer a good choice for implant patients 
in the future. Dentists are already paying attention to underlying bone loss around 
those implants also used in patients with a low gingival index. 
Collagenase-3/MMP-13, collagenase-2/MMP-8, and gelatinase-B/MMP-9 were well 
correlated in this study with irreversible peri-implant vertical bone loss. 
Measurements of collagenase-3 and collagenase-2 or gelatinase-B in PISF could 
therefore sever as biomarkers to indicate the degree of peri-implant vertical bone loss. 
These findings offer new insights into the pathomechanisms contributing to loosening 
of dental implants, although the exact site and mode of action remain unclear. 
9.3 Gingival index and gelatinase-B
It is generally assumed that a similar pathological process is shared by chronic 
periodontitis and loosening of dental implants (Meffert, 1996). The main clinical 
symptoms are quite similar. These are an enhanced probing pocket depth or implant 
pocket depth, bleeding on probing, and increasing tooth or implant mobility 
(Mombelli et al., 1987; O'Reilly and Claffey, 1996). Besides gingival index, many 
other clinical indices have been established in periodontology, including plaque index 
(Silness and Löe, 1964), periodontal index (Russell, 1967), and periodontal disease 
index (Ramfjord, 1967). Some of the periodontal indices have been further modified 
and introduced to implantology (Mombelli et al., 1987; Luterbacher et al., 2000). 
They are useful in the evaluation of degree of peri-implantitis in the clinic and in 
research and are used in clinical trials. 
In addition to indices, molecular medicine has dramatically developed in the past 
three decades. Currently, some new molecular diagnostic markers identified in 
laboratories are being introduced as clinical chair-side tests (Sorsa et al., 1999; 
Mancini et al., 1999). Gelatinase B/MMP-9 has not been analyzed in such a clinical 
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setting. In vivo activated gelatinase-B/MMP-9 levels in PISF seem to be reflected in 
gingival index when it is higher than 0.5. This combination of gingival index and 
gelatinase-B may help clinical dentists in recognition of patients at risk for peri-
implant bone loss.  
9.4 Collagenase-cleaved type I collagen fragment and chronic periodontitis
It is widely accepted that degradation of type I collagen during periodontitis 
progression is mediated through mammalian proteinases, not bacterial enzymes (Sorsa 
et al., 1992; van der Zee et al., 1997; Sorsa et al., 1999). Pathogenic bacteria have 
been reported to affect host cells, which are producing proteinases at four levels. 
Bacterial components are chemotactic and induce host cells to produce chemokines 
(Miller et al., 1975). Polymorphonuclear leukocytes release MMPs when bacteria are 
phagocytosed (Ding et al., 1997). Bacterial membrane can induce polymorphonuclear 
leukocytes to produce MMPs (Ding et al., 1996). The bacterial proteinases activate 
proMMPs, which is a rate-limiting step (Sorsa et al., 1992; Okamoto et al., 1997). No 
direct evidence has been available, however, on actual collagenlysis mediated by the 
classical mammalian collagenases. 
Collagenase-cleaved type I collagen neoepitope/COL1-3/4C staining was detected in 
the matrix associated with the sulcular and junctional epithelium. Collagenase-1 is not 
found in periodontal pocket epithelium (Woolley and Davies, 1981; Ingman et al., 
1996), but collagenase-2 and collagenase-3 have been detected in the pocket 
epithelium (Uitto et al. 1998; Tervahartiala et al., 2000). Collagenases produced in the 
pocket epithelium seem to become activated and to be able to cleave across the 
collagen fibril triple helices. Apparently, they overcome their endogenous proteinase 
inhibitor (TIMP) shield. This is important for the formation and progression of 
periodontal pockets as assessed from the microanatomical location of the COL1-3/4C 
neoepitope. 
COL1-3/4C staining was detected in the matrix surrounding some of the fibroblasts. 
Fibroblasts produce low levels of collagenase-1 (Kubota et al., 1996; Dahan et al.,
2001). Collagenase-2 has not been found in gingival fibroblasts, but has been 
described in periodontal ligament fibroblasts (Salo et al., 1995). Collagenase-3 is 
expressed by gingival fibroblasts (Uitto et al., 1998; Tervahartiala et al., 2000). These 
results imply that collagenases produced by some of the interstitial fibroblasts can 
contribute to local and pericellular collagenolysis. 
COL1-3/4C staining was discovered in the interstitial matrix infiltrated by 
inflammatory cells, and much of the interstitial collagen was destroyed in such 
inflammatory areas. This is compatible with findings describing collagenases in 
monocytes/macrophages. Collagenase-1 was found in macrophages in the 1970's 
(Wahl et al., 1974). Collagenase-2 and -3 mRNA and the corresponding enzyme 
proteins have been detected in monocyte/macrophage-like cells (Uitto et al., 1998; 
Tervahartiala et al., 2001). Collagenase-2 among the three collagenases is the most 
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effective collagenase in the cleavage of type I collagen (Hasty et al., 1987). Pro-
collagenases which have accumulated in the extracellular matrix can become locally 
activated and lead to collagen-fibril destruction (van der Zee et al., 1996). Almost 
70% of the collagen in gingival tissue is degraded in one inflammation cycle (Bartold 
et al., 2000). Direct morphological evidence is now reported here for the first time 
demonstrating that collagenases mediate collagen-fibril breakdown in gingival tissue 
in chronic periodontitis. 
9.5 Cellular fibronectin in chronic periodontitis and loosening
Research on extracellular matrix and proteolytic enzymes has changed our views on 
periodontitis. One of the serine proteinases is human neutrophil elastase. Elastase 
activities in gingival crevicular fluid and in the saliva of chronic periodontitis patients 
are significantly increased compared with activities in healthy controls, but they 
decrease in GCF after periodontal treatments such as scaling, root planning, and 
curettage (Ingman et al., 1994). The increased elastase levels in GCF and saliva have 
been proposed as useful biochemical markers to monitor the course and treatment of 
chronic periodontitis (Ingman et al., 1994; Uitto et al., 1996). 
Every enzyme shows some substrate specificity. Elastase in vivo has been able to 
degrade fibronectin to fibronectin fragments (McDonald et al., 1992). Cellular 
fibronectin staining was in our study found in gingival connective tissue. Elastase-
positive cells have been also found in gingival tissue (Ingman et al., 1994). It has been 
tentatively considered to be the main proteolytic enzyme responsible for the 
degradation of fibronectin in skin wounds (Grinnell and Zhu, 1996; Herrick et al., 
1997). It removes fibronectin from human basement membranes, as has been shown 
by an electron microscopic study (Morris et al., 1993; Bonnefoy and Legrand, 2000). 
A conclusion which might be drawn from these previous studies and the present study 
is that the decreased staining of cellular fibronectin may be the result of increased 
elastase activity. This is supported by previous studies of biochemical markers in 
GCF, which found high levels of fibronectin fragments in GCF at periodontal disease 
sites. The level of fragments decreased after periodontal treatment (Lopatin et al., 
1989; Talonpoika et al., 1989). These findings, together with the present quantitative 
morphometric results, suggest that increased human neutrophil elastase activities in 
GCF and cellular fibronectin fragments may prove useful markers for progressive 
connective tissue degradation in chronic periodontitis. This relationship between 
elastase and cellular fibronectin staining probably explains the decreased cellular 
fibronectin in chronic periodontitis.  
Elastase activities were not up-regulated in PISF or saliva, not even in severe peri-
implantitis. Overexpression of cellular fibronectin around loosening dental implants 
would seem to be due to increased local synthesis combined with relatively modest 
degradation. In fibroblast cell culture, titanium (Ti) can significantly enhance 
expression of cell fibronectin (Chou et al., 1996). Cellular fibronectin staining was 
higher in loosening of our dental implants. To evaluate this in some depth, we 
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compared our findings with some studies of aseptic loosening of total hip 
replacements. Elastase activity is increased in interface tissue extracts and joint fluid 
(Takagi et al., 1995). Expression of cellular fibronectin is not decreased, but increased 
in interface tissues (Li et al., 2000). It seems that, in aseptic loosening of totally 
replaced hips, the stimulators of cellular fibronectin synthesis greatly surpass the 
influences of proteinase-mediated degradation. The difference between loosening of 
dental implants and aseptic loosening of totally replaced hips is that there are many 
more foreign bodies (debris) around loosening hip implants than around the loosening 
dental implants. The (sub)micron-size particles around the hip arise as a result of 
cyclic loading (=walking) and friction and abrasion between the gliding surfaces of 
the head of the femoral stem and the acetabular cup (Campbell et al., 1995). It has 
been calculated that in a metal-to-(conventional) polyethylene joint composite, more 
than 100,000 particles of ultra-high molecular weight polyethylene (Wagner and 
Wagner, 2001) are formed at every step and that normally a patient takes about more 
than 106 steps per year (Silva et al., 2002). The number of particles has been found to 
range from 8.5 x 108 to 5.7 x 1011 per gram of dry tissue weight (Vaughn et al., 1999). 
Changes in extracellular matrix are considered a reflection of cellular history and 
initiate various cascades (Nathan et al., 1991). Increased expression of cellular 
fibronectin might be viewed as a result of periprosthetic host responses. 
9.6 Osteoclast-stimulating cytokine network in loosening and periodontitis
Parts of old bone are placed by new bone to maintain bone strength. This is possible 
due to dynamic bone remodeling cycles (Blair, 1998). The cycle is normally balanced 
by an essential coupling between bone resorption and formation (Schwartz et al., 
1997). Cytokines regulate osteoclast, and osteoblast formation and their functions 
(Schwartz et al., 1997; Blair, 1998; Raisz, 1999), and can be categorized into 
osteoclast- and osteoblast-regulating cytokines, although both cells can be affected. 
Pathological bone resorption is suggested to be driven by an excess of cytokines, 
which stimulate osteoclasts or inhibit osteoblasts (Oates and Cochran, 1996; 
Konttinen et al., 1997). 
The in vivo working concentrations of cytokines on osteoclasts are not yet known. 
The fact that osteoclast-stimulating cytokines can be visualized using a staining 
method has been established in our laboratory (Konttinen et al., 1997; Xu et al. 2000). 
When TNF-?, IL-1?, IL-6, PDGF-A, and TGF-? were studied in loosening of dental 
implants and in chronic periodontitis, TNF-?, IL-1?, and IL-6 were increased in 
loosening of dental implants and in chronic periodontitis. Titanium stimulates release 
of IL-1?, IL-6, and TNF-? from macrophages and fibroblasts (Manlapaz et al., 1996; 
Wang et al., 1996). Foreign body giant cells were seen in peri-implantitis. If 
macrophages encounter an implant and/or particles too large to be phagocytosed, they 
form foreign body giant cells (Mariano and Spector, 1974). These foreign body giant 
cells seem to have a high capacity to produce osteoclast-stimulating cytokines. All the 
foreign body giant cells always contained all of the osteoclast-stimulating cytokine 
analyzed. As to cytokine profile, chronic periodontitis and peri-implantitis were quite 
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similar, but not completely identical. Both are characterized by a progressive loss of 
bone support tissue. 
Overlapping effects may be necessary to guarantee efficient osteolysis (Goldring and 
Goldring, 1996). TNF-? stimulates the production of IL-1? and IL-6. IL-1? has been 
considered particularly important in osteolysis during loosening. TNF-? has already 
been studied in chronic periodontitis (Lindemann et al., 1988; Tervahartiala et al., 
2001). Because cytokine expression in peri-implantitis is limited to IL-1?, TNF-?,
and IL-6, peri-implantitis might be particularly amenable to treatment with biological 
cytokine modulators like IL-1 receptor antagonist, TNF-? antibodies, or soluble TNF-
receptors (Graves, 1999). In chronic periodontitis and peri-implantitis, it may be 
possible to manage with a local application to the gingival and peri-implant pockets, 
perhaps using carriers enabling prolonged and/or controlled local release. 
Although some new and interesting findings were made in this thesis study, the 
limitations of the small sample size should be taken into consideration. Samples were 
obtained from patients representing regular dental implant surgery patients. Although 
they are representative, they still represent a small sample population. On the other 
hand, in the interpretation generally accepted statistical methods were used, and they 
take the uncertainty caused by the small sample size into consideration. Still, 
confirmation of these findings by other groups is needed and further research with 
larger sample size and refined methods will provide valuable information. 
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Figure 6: Our hypothetical findings of adverse tissue responses leading to peri-implant tissue destruction 
Increased osteoclast-stimulating cytokines regulate (V)    ? Elastase (periodontitis) causes (III) 
     ?        ?
Peri-implant bone loss?   ?Type I collagen degradation ? Cellular fibronectin?   
   ?lead to bone loss   ? responsible               ? induce 
?not correlated Collagenase-2? (I)   Pocket epithelium (IV)     Implant particles (III) 
   Collagenase-3? (I)   Gingival fibroblasts 
mGI > 0.5  reflects ? Gelatinase-B? (II)   Monocytes/macrophages 
Roman numerals refer to the original publications. 
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SUMMARY AND CONCLUSIONS 
Loosening of dental implants is an important problem. Bioincompatible implant 
materials constitute one of the important risk factors which cause an adverse host 
response in peri-implant tissues. Adverse host responses lead to activation of multiple 
biological and pathological cascades. The pathological feature is the progressive loss 
of peri-implant support tissues. Many proteolytic enzymes participate in the process. 
Major conclusions: 
I. Collagenase-3/MMP-13 and collagenase-2/MMP-8 in peri-implant sulcus fluid, 
produced by adjacent bone osteoclast cells, neutrophils, and mesenchymal cells, 
reflect irreversible peri-implant vertical bone loss around loosening dental implants. 
Measurements of collagenase-3 and/or collagenase-2 could serve as markers to 
indicate the degree of peri-implant vertical bone loss. 
II. Gelatinase-B/MMP-9 is associated with peri-implant bone loss. Activation of 
gelatinase-B/MMP-9, together with elevated modified gingival index (> 0.5), 
eventually reflect active phases of peri-implantitis. These may prove to be 
diagnostically useful indicators. 
III. In the immunohistochemical expression of cellular fibronectin in loosening of 
dental implants and chronic periodontitis, distinct quantitative differences exist. These 
differences suggest that different pathomechanisms are operative in loosening of 
dental implants and natural teeth. It is necessary to improve the biocompatibility of 
dental implant materials and to better understand the pathomechanisms of loosening 
to be able to improve the long-term results for dental implants. 
VI. Expression of collagenase-cleaved collagen neoepitopes suggests that the host-
cell-derived collagenases are able to cleave across the triple helical collagen fibrils in 
situ. Collagenases become activated and overcome their endogenous tissue inhibitors 
at the sulcular and junctional epithelial attachment and monocyte/macrophage-
infiltrated areas. Collagenases may contribute to the initiation and progression of 
periodontal tissue destruction or attachment loss with deepening of periodontal 
pockets in chronic periodontitis. 
V. The osteoclast-activating cytokine network (TNF-?, IL-1?, IL-6, PDGF-A, and 
TGF-?) was activated in both peri-implantitis and chronic periodontitis, but the 
cytokine profiles differed. During loosening of dental implants, this activation may 
contribute to peri-implant bone loss and may be an amenable target for local therapies 
with cytokine modulators. 
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